drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB08820 | DB11652 | 1,478 | 1,155 | [
"DDInter997",
"DDInter1891"
] | Ivacaftor | Tucatinib | Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012, and by Health Canada in late 2012. Ivacaftor is administered as a monotherapy and... | Tucatinib is a kinase inhibitor drug used with [trastuzumab] and [capecitabine] in the treatment of unresectable or metastatic HER-2 positive breast cancer. It was developed by Seattle Genetics and approved by the FDA on April 17, 2020. Tucatinib is a promising new treatment for patients with metastatic breast cancer w... | Major | 2 | [
[
[
1478,
25,
1155
]
],
[
[
1478,
63,
1101
],
[
1101,
23,
1155
]
],
[
[
1478,
64,
609
],
[
609,
24,
1155
]
],
[
[
1478,
63,
522
],
[
522,
... | [
[
[
"Ivacaftor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tucatinib"
]
],
[
[
"Ivacaftor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
... | Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Tucatinib
Ivacaftor may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may cau... |
DB00774 | DB01129 | 1,577 | 379 | [
"DDInter889",
"DDInter1559"
] | Hydroflumethiazide | Rabeprazole | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p822) | Rabeprazole is an antiulcer drug in the class of proton pump inhibitors. It is a prodrug - in the acid environment of the parietal cells it turns into active sulphenamide form. Rabeprazole inhibits the H+, K+ATPase of the coating gastric cells and dose-dependent oppresses basal and stimulated gastric acid secretion. | Moderate | 1 | [
[
[
1577,
24,
379
]
],
[
[
1577,
63,
1215
],
[
1215,
40,
379
]
],
[
[
1577,
63,
660
],
[
660,
1,
379
]
],
[
[
1577,
21,
29232
],
[
29232,
... | [
[
[
"Hydroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rabeprazole"
]
],
[
[
"Hydroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lansoprazo... | Hydroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Lansoprazole and Lansoprazole (Compound) resembles Rabeprazole (Compound)
Hydroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Esomeprazole and Esomeprazole (Compound) resembl... |
DB00330 | DB00515 | 238 | 589 | [
"DDInter689",
"DDInter387"
] | Ethambutol | Cisplatin | Ethambutol is a bacteriostatic agent indicated alongside medications such as [isoniazid], [rifampin], and [pyrazinamide] in the treatment of pulmonary tuberculosis. Ethambutol was first described in the literature in 1961. It was developed out of a need for therapies active against isoniazid resistant strains of _Mycob... | Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also incl... | Moderate | 1 | [
[
[
238,
24,
589
]
],
[
[
238,
21,
28778
],
[
28778,
60,
589
]
],
[
[
238,
24,
1468
],
[
1468,
63,
589
]
],
[
[
238,
63,
367
],
[
367,
... | [
[
[
"Ethambutol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cisplatin"
]
],
[
[
"Ethambutol",
"{u} (Compound) causes {v} (Side Effect)",
"Anaphylactic shock"
],
[
"Anaphylactic shock",
"{u} (Sid... | Ethambutol (Compound) causes Anaphylactic shock (Side Effect) and Anaphylactic shock (Side Effect) is caused by Cisplatin (Compound)
Ethambutol may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when tak... |
DB00376 | DB01619 | 1,105 | 830 | [
"DDInter1870",
"DDInter1441"
] | Trihexyphenidyl | Phenindamine | Trihexyphenidyl is a centrally acting muscarinic antagonist used for treatment of parkinsonism and drug-induced extrapyramidal disorders.[L31773,L31778] Its discovery was published in 1949 in a study looking for drugs with antispasmodic activity. Trihexyphenidyl is rarely used in the treatment of parkinsonism, and is n... | Phenindamine is an antihistamine. Phenindamine blocks the effects of the naturally occurring chemical histamine in your body. Antihistamines such as phenindamine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine ... | Moderate | 1 | [
[
[
1105,
24,
830
]
],
[
[
1105,
24,
537
],
[
537,
40,
830
]
],
[
[
1105,
24,
13
],
[
13,
24,
830
]
],
[
[
1105,
24,
104
],
[
104,
1... | [
[
[
"Trihexyphenidyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenindamine"
]
],
[
[
"Trihexyphenidyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclizine"
... | Trihexyphenidyl may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine (Compound) resembles Phenindamine (Compound)
Trihexyphenidyl may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine may cause a moderate inte... |
DB09076 | DB09488 | 1,116 | 103 | [
"DDInter1899",
"DDInter23"
] | Umeclidinium | Acrivastine | Umeclidinium is a long-acting muscarinic antagonist (LAMA) used as a maintenance treatment for symptoms of chronic obstructive pulmonary disease (COPD). COPD is a progressive obstructive lung disease characterized by shortness of breath, cough, sputum production, and chronically poor airflow with a forced expiratory vo... | Acrivastine is a triprolidine analog antihistamine indicated for the treatment of allergies and hay fever. As an H1 receptor antagonist, it functions by blocking the action of histamine at this receptor thereby preventing the symptoms associated with histamine release such as pruritis, vasodilation, hypotension, edema,... | Moderate | 1 | [
[
[
1116,
24,
103
]
],
[
[
1116,
63,
1405
],
[
1405,
24,
103
]
],
[
[
1116,
24,
412
],
[
412,
24,
103
]
],
[
[
1116,
24,
1536
],
[
1536,
... | [
[
[
"Umeclidinium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acrivastine"
]
],
[
[
"Umeclidinium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclobenzaprine"
]... | Umeclidinium may cause a moderate interaction that could exacerbate diseases when taken with Cyclobenzaprine and Cyclobenzaprine may cause a moderate interaction that could exacerbate diseases when taken with Acrivastine
Umeclidinium may cause a moderate interaction that could exacerbate diseases when taken with Eluxad... |
DB00999 | DB06292 | 504 | 549 | [
"DDInter883",
"DDInter474"
] | Hydrochlorothiazide | Dapagliflozin | Hydrochlorothiazide is the most commonly prescribed thiazide diuretic. It is indicated to treat edema and hypertension.[A185138,L8447,L8450] Hydrochlorothiazide use is common but declining in favour of angiotensin converting enzyme inhibitors. Many combination products are available containing hydrochlorothiazide and a... | Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and it was the first SLGT2 inhibitor to be approved. indicated for managing diabetes mellitus type 2. When combined with diet and exercise in adults, dapagliflozin helps to improve glycemic control by inhibiting glucose reabsorption in the proximal tu... | Moderate | 1 | [
[
[
504,
24,
549
]
],
[
[
504,
24,
1344
],
[
1344,
40,
549
]
],
[
[
504,
21,
28882
],
[
28882,
60,
549
]
],
[
[
504,
63,
1179
],
[
1179,
... | [
[
[
"Hydrochlorothiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
]
],
[
[
"Hydrochlorothiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagl... | Hydrochlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin and Canagliflozin (Compound) resembles Dapagliflozin (Compound)
Hydrochlorothiazide (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Dapag... |
DB01764 | DB06605 | 805 | 1,409 | [
"DDInter469",
"DDInter108"
] | Dalfopristin | Apixaban | Dalfopristin is a combination of two antibiotics (Dalfopristin and quinupristin) used to treat infections by staphylococci and by vancomycin-resistant Enterococcus faecium. It is not effective against Enterococcus faecalis infections. Dalfopristin inhibits the early phase of protein synthesis in the bacterial ribosome ... | Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FD... | Moderate | 1 | [
[
[
805,
24,
1409
]
],
[
[
805,
6,
8374
],
[
8374,
45,
1409
]
],
[
[
805,
25,
1670
],
[
1670,
63,
1409
]
],
[
[
805,
24,
1593
],
[
1593,
... | [
[
[
"Dalfopristin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apixaban"
]
],
[
[
"Dalfopristin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)... | Dalfopristin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Apixaban (Compound)
Dalfopristin may lead to a major life threatening interaction when taken with Eliglustat and Eliglustat may cause a moderate interaction that could exacerbate diseases when taken with Apixaban
Dalfopristin may cause a moderate... |
DB00281 | DB00418 | 608 | 536 | [
"DDInter1066",
"DDInter1650"
] | Lidocaine | Secobarbital | Ever since its discovery and availability for sale and use in the late 1940s, lidocaine has become an exceptionally commonly used medication. In particular, lidocaine's principal mode of action in acting as a local anesthetic that numbs the sensations of tissues means the agent is indicated for facilitating local anest... | Secobarbital (marketed by Eli Lilly and Company under the brand names Seconal and Tuinal) is a barbiturate derivative drug with anaesthetic, anticonvulsant, sedative and hypnotic properties. It is commonly known as quinalbarbitone in the United Kingdom. | Minor | 0 | [
[
[
608,
23,
536
]
],
[
[
608,
23,
1023
],
[
1023,
1,
536
]
],
[
[
608,
62,
288
],
[
288,
1,
536
]
],
[
[
608,
6,
3486
],
[
3486,
45... | [
[
[
"Lidocaine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Secobarbital"
]
],
[
[
"Lidocaine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Pentobarbital"
],
[
... | Lidocaine may cause a minor interaction that can limit clinical effects when taken with Pentobarbital and Pentobarbital (Compound) resembles Secobarbital (Compound)
Lidocaine may cause a minor interaction that can limit clinical effects when taken with Butalbital and Butalbital (Compound) resembles Secobarbital (Compou... |
DB01203 | DB09038 | 699 | 1,450 | [
"DDInter1255",
"DDInter636"
] | Nadolol | Empagliflozin | Nadolol is a nonselective beta adrenal receptor blocker that is used to lower blood pressure.[L7922,L7925] Nonselective beta adrenal receptor blockers may no longer be first line in the treatment of hypertension as newer generations of beta adrenal receptor blockers have higher selectivity and offer better rates of adv... | Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 dia... | Moderate | 1 | [
[
[
699,
24,
1450
]
],
[
[
699,
25,
659
],
[
659,
63,
1450
]
],
[
[
699,
74,
1061
],
[
1061,
24,
1450
]
],
[
[
699,
63,
1486
],
[
1486,
... | [
[
[
"Nadolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Nadolol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vilanterol"
],
[
"Vilanterol",
... | Nadolol may lead to a major life threatening interaction when taken with Vilanterol and Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Nadolol (Compound) resembles Treprostinil (Compound) and Nadolol may cause a moderate interaction that could exacerbate disease... |
DB01114 | DB01246 | 272 | 820 | [
"DDInter362",
"DDInter45"
] | Chlorpheniramine | Alimemazine | A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than promethazine. | A phenothiazine derivative that is used as an antipruritic. | Moderate | 1 | [
[
[
272,
24,
820
]
],
[
[
272,
24,
358
],
[
358,
24,
820
]
],
[
[
272,
63,
104
],
[
104,
40,
820
]
],
[
[
272,
40,
11275
],
[
11275,
... | [
[
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
]
],
[
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orphenadrine"
... | Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Orphenadrine and Orphenadrine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine
Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Meth... |
DB00501 | DB09330 | 752 | 985 | [
"DDInter380",
"DDInter1352"
] | Cimetidine | Osimertinib | A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant ... | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the ... | Moderate | 1 | [
[
[
752,
24,
985
]
],
[
[
752,
23,
112
],
[
112,
23,
985
]
],
[
[
752,
63,
608
],
[
608,
23,
985
]
],
[
[
752,
24,
1478
],
[
1478,
2... | [
[
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Cimetidine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Osimertinib
Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lido... |
DB00432 | DB10989 | 1,083 | 496 | [
"DDInter1868",
"DDInter858"
] | Trifluridine | Hepatitis A Vaccine | Trifluridine is a fluorinated pyrimidine nucleoside that is structurally related to [idoxuridine]. It is an active antiviral agent in ophthalmic solutions used mainly in the treatment of primary keratoconjunctivitis and recurrent epithelial keratitis due to herpes simplex virus. It displays effective antiviral activity... | Hepatitis A viral infection can lead to significant morbidity and mortality, with signs and symptoms that include anorexia, nausea, vomiting, and liver failure. Known by several trade names, such as Havrix and Twinrix, the Hepatitis A vaccine has been formulated for immunization against hepatitis A virus (HAV) infectio... | Moderate | 1 | [
[
[
1083,
24,
496
]
],
[
[
1083,
24,
4
],
[
4,
24,
496
]
],
[
[
1083,
24,
738
],
[
738,
63,
496
]
],
[
[
1083,
25,
976
],
[
976,
24,... | [
[
[
"Trifluridine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
]
],
[
[
"Trifluridine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine me... | Trifluridine may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine
Trifluridine may cause a moderate interaction that could exacerbate dis... |
DB06414 | DB06626 | 655 | 263 | [
"DDInter703",
"DDInter147"
] | Etravirine | Axitinib | Etravirine is an antiretroviral agent more specifically classified as a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI). Etraverine is used clinically for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. On January 18, 2007, the FDA granted accelerated approved for the use of etravirine 10... | Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3). Through this mechanism of action, axitinib blocks angiogenesis, tumour growth and metastases. It is reported to exhibit potency that is 50-450 times hi... | Major | 2 | [
[
[
655,
25,
263
]
],
[
[
655,
63,
660
],
[
660,
23,
263
]
],
[
[
655,
62,
1194
],
[
1194,
23,
263
]
],
[
[
655,
63,
392
],
[
392,
2... | [
[
[
"Etravirine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Axitinib"
]
],
[
[
"Etravirine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Esomeprazole"
],
[
"Esomeprazo... | Etravirine may cause a moderate interaction that could exacerbate diseases when taken with Esomeprazole and Esomeprazole may cause a minor interaction that can limit clinical effects when taken with Axitinib
Etravirine may cause a minor interaction that can limit clinical effects when taken with Ranitidine and Ranitidi... |
DB00581 | DB01021 | 355 | 674 | [
"DDInter1018",
"DDInter1861"
] | Lactulose | Trichlormethiazide | Lactulose is a synthetic disaccharide derivative of lactose that is most commonly used as a laxative agent despite also being formally indicated to serve as an adjunct therapy in treating portal-systemic encephalopathy (PSE).[FDA Label,L6199,L6202] Despite being first synthesized in 1929, investigations regarding its p... | A thiazide diuretic with properties similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p830) | Moderate | 1 | [
[
[
355,
24,
674
]
],
[
[
355,
63,
1014
],
[
1014,
40,
674
]
],
[
[
355,
24,
178
],
[
178,
1,
674
]
],
[
[
355,
24,
359
],
[
359,
40... | [
[
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trichlormethiazide"
]
],
[
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Benzthiazide"
],
... | Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Benzthiazide and Benzthiazide (Compound) resembles Trichlormethiazide (Compound)
Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Polythiazide and Polythiazide (Compound) resembles Trichlor... |
DB00675 | DB11986 | 888 | 484 | [
"DDInter1744",
"DDInter648"
] | Tamoxifen | Entrectinib | Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment ... | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positi... | Moderate | 1 | [
[
[
888,
24,
484
]
],
[
[
888,
23,
1247
],
[
1247,
23,
484
]
],
[
[
888,
25,
271
],
[
271,
23,
484
]
],
[
[
888,
24,
1539
],
[
1539,
... | [
[
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Tamoxifen",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[... | Tamoxifen may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Entrectinib
Tamoxifen may lead to a major life threatening interaction when taken with Mirabegron and Mirabegron may... |
DB00853 | DB11003 | 1,686 | 748 | [
"DDInter1762",
"DDInter100"
] | Temozolomide | Anthrax vaccine | Refractory anaplastic astrocytoma (WHO grade III) and Glioblastoma multiforme (WHO grade IV) are primary malignant brain tumours with poor prognosis and limited treatment options. Despite considerable genetic heterogeneity, these tumours often have impaired DNA repair systems, rendering them initially sensitive to alky... | Anthrax vaccine is a vaccine used for the pre- or post-exposure prophylaxis of disease in those at high risk of, suspected or confirmed exposure to *Bacillus anthracis*. It is subcutaneously or intramuscularly administered. It is derived from cell-free filtrates of microaerophilic cultures of an avirulent, nonencapsula... | Moderate | 1 | [
[
[
1686,
24,
748
]
],
[
[
1686,
63,
322
],
[
322,
24,
748
]
],
[
[
1686,
24,
995
],
[
995,
24,
748
]
],
[
[
1686,
25,
676
],
[
676,
... | [
[
[
"Temozolomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Temozolomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
],... | Temozolomide may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Temozolomide may cause a moderate interaction that could exacerbate diseases when taken with Hydroxyurea ... |
DB00087 | DB06273 | 599 | 980 | [
"DDInter41",
"DDInter1824"
] | Alemtuzumab | Tocilizumab | Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52. The Campath-1H antibody is an IgG1 kappa with the human variable framework and constant region... | Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions. It was first described in the literature in 2003 when Chugai, a subsidiary of Roche began developing IL-6 inhibiting monoclonal antibodies. Tocilizumab was granted FDA approval on 8 J... | Moderate | 1 | [
[
[
599,
24,
980
]
],
[
[
599,
24,
139
],
[
139,
24,
980
]
],
[
[
599,
24,
110
],
[
110,
63,
980
]
],
[
[
599,
63,
491
],
[
491,
24,... | [
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tocilizumab"
]
],
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zidovudine"
],
[... | Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Zidovudine and Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Tocilizumab
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Polatuzumab vedoti... |
DB00241 | DB01254 | 288 | 1,213 | [
"DDInter257",
"DDInter484"
] | Butalbital | Dasatinib | Butalbital, or 5-allyl-5-isobutylbarbituric acid, is a derivative of barbituric acid which the hydrogens at position 5 are substituted by an allyl group and an isobutyl group. It is a short-to-intermediate acting member of barbiturates that exhibit muscle-relaxing and anti-anxiety properties that produce central nervou... | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the break... | Moderate | 1 | [
[
[
288,
24,
1213
]
],
[
[
288,
24,
112
],
[
112,
23,
1213
]
],
[
[
288,
24,
1135
],
[
1135,
62,
1213
]
],
[
[
288,
24,
1320
],
[
1320,
... | [
[
[
"Butalbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
]
],
[
[
"Butalbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
... | Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Dasatinib
Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Nalo... |
DB09075 | DB12015 | 498 | 1,033 | [
"DDInter621",
"DDInter53"
] | Edoxaban | Alpelisib | Edoxaban is a member of the Novel Oral Anti-Coagulants (NOACs) class of drugs, and is a rapidly acting, oral, selective factor Xa inhibitor. By inhibiting factor Xa, a key protein in the coagulation cascade, edoxaban prevents the stepwise amplification of protein factors needed to form blood clots. It is indicated to r... | Alpelisib is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potent antitumor activity. It works by selectively inhibiting class I PI3K p110α , which is the catalytic subunit of PI3K, a lipid kinase that plays a role in various biological processes, including proliferation, survival, differentiation, and metaboli... | Major | 2 | [
[
[
498,
25,
1033
]
],
[
[
498,
24,
738
],
[
738,
24,
1033
]
],
[
[
498,
64,
772
],
[
772,
24,
1033
]
],
[
[
498,
63,
758
],
[
758,
... | [
[
[
"Edoxaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Alpelisib"
]
],
[
[
"Edoxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
],
[
"Niraparib",
... | Edoxaban may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Edoxaban may lead to a major life threatening interaction when taken with Carvedilol and Carvedilol may cause a moder... |
DB00238 | DB00687 | 188 | 870 | [
"DDInter1285",
"DDInter747"
] | Nevirapine | Fludrocortisone | A potent, non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with nucleoside analogues for treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection and AIDS. Structurally, nevirapine belongs to the dipyridodiazepinone chemical class. | Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to... | Moderate | 1 | [
[
[
188,
24,
870
]
],
[
[
188,
24,
1220
],
[
1220,
40,
870
]
],
[
[
188,
21,
28835
],
[
28835,
60,
870
]
],
[
[
188,
24,
659
],
[
659,
... | [
[
[
"Nevirapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
]
],
[
[
"Nevirapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
... | Nevirapine may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone (Compound) resembles Fludrocortisone (Compound)
Nevirapine (Compound) causes Hyperglycaemia (Side Effect) and Hyperglycaemia (Side Effect) is caused by Fludrocortisone (Compound)
Nevirapine may cau... |
DB00836 | DB01036 | 543 | 211 | [
"DDInter1088",
"DDInter1832"
] | Loperamide | Tolterodine | Loperamide is an anti-diarrheal agent that is available as various over-the-counter products for treating diarrhea. The drug was first synthesized in 1969 and used medically in 1976. It is a highly lipophilic synthetic phenylpiperidine opioid that is structurally similar to opiate receptor agonists such as [diphenoxyla... | Tolterodine is an antimuscarinic drug that is used to treat urinary incontinence. Tolterodine acts on M2 and M3 subtypes of muscarinic receptors. | Moderate | 1 | [
[
[
543,
24,
211
]
],
[
[
543,
24,
358
],
[
358,
40,
211
]
],
[
[
543,
63,
494
],
[
494,
40,
211
]
],
[
[
543,
63,
128
],
[
128,
24,... | [
[
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolterodine"
]
],
[
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orphenadrine"
],
[... | Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Orphenadrine and Orphenadrine (Compound) resembles Tolterodine (Compound)
Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Disopyramide and Disopyramide (Compound) resembles Tolterodine (... |
DB00195 | DB00981 | 726 | 1,528 | [
"DDInter198",
"DDInter1462"
] | Betaxolol (ophthalmic) | Physostigmine | Betaxolol is a propanolamine that is 3-aminopropane-1,2-diol in which the hydrogen of the primary hydoxy is substituted by a 4-[2-(cyclopropylmethoxy)ethyl]phenyl group and one of the hydrogens attached to the amino group is substituted by isopropyl. It is a selective beta1-receptor blocker and is used in the treatment... | A cholinesterase inhibitor that is rapidly absorbed through membranes. It can be applied topically to the conjunctiva. It also can cross the blood-brain barrier and is used when central nervous system effects are desired, as in the treatment of severe anticholinergic toxicity. | Moderate | 1 | [
[
[
726,
24,
1528
]
],
[
[
726,
5,
11595
],
[
11595,
44,
1528
]
],
[
[
726,
21,
28658
],
[
28658,
60,
1528
]
],
[
[
726,
1,
887
],
[
887,
... | [
[
[
"Betaxolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Physostigmine"
]
],
[
[
"Betaxolol",
"{u} (Compound) treats {v} (Disease)",
"glaucoma"
],
[
"glaucoma",
"{u} (Disease) is treated by {v... | Betaxolol may cause a moderate interaction that could exacerbate diseases when taken with Physostigmine
Betaxolol (Compound) treats glaucoma (Disease) and glaucoma (Disease) is treated by Physostigmine (Compound)
Betaxolol (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Physostigmine (C... |
DB00087 | DB10343 | 599 | 962 | [
"DDInter41",
"DDInter160"
] | Alemtuzumab | Bacillus calmette-guerin substrain tice live antigen | Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52. The Campath-1H antibody is an IgG1 kappa with the human variable framework and constant region... | Bacillus calmette-guerin substrain tice live antigen is a vaccine containing attenuated live culture preparation of the Bacillus of Calmette and Guerin (BCG) strain of *Mycobacterium bovis* for percutaneous use. It is administered to prevent the development of tuberculosis. | Major | 2 | [
[
[
599,
25,
962
]
],
[
[
599,
24,
617
],
[
617,
24,
962
]
],
[
[
599,
63,
1057
],
[
1057,
25,
962
]
],
[
[
599,
24,
1342
],
[
1342,
... | [
[
[
"Alemtuzumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bacillus calmette-guerin substrain tice live antigen"
]
],
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
... | Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Budesonide and Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Bacillus calmette-guerin substrain tice live antigen
Alemtuzumab may cause a moderate interaction that could exacerbate di... |
DB00092 | DB14962 | 58 | 1,363 | [
"DDInter40",
"DDInter1847"
] | Alefacept | Trastuzumab deruxtecan | Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD. | Trastuzumab deruxtecan is a HER2-directed antibody attached to a topoisomerase inhibitor that is approved for use in certain types of treatment-resistant HER2-positive cancers. It is classified as an antibody-drug conjugate. The cleavable peptide linker used to bind the antibody and drug in this product distinguishes i... | Moderate | 1 | [
[
[
58,
24,
1363
]
],
[
[
58,
24,
1430
],
[
1430,
24,
1363
]
],
[
[
58,
63,
599
],
[
599,
24,
1363
]
],
[
[
58,
25,
1259
],
[
1259,
... | [
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trastuzumab deruxtecan"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
... | Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab deruxtecan
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Alemtuz... |
DB00247 | DB00357 | 1,131 | 1,051 | [
"DDInter1194",
"DDInter71"
] | Methysergide | Aminoglutethimide | An ergot derivative that is a congener of lysergic acid diethylamide. It antagonizes the effects of serotonin in blood vessels and gastrointestinal smooth muscle, but has few of the properties of other ergot alkaloids. Methysergide is used prophylactically in migraine and other vascular headaches and to antagonize sero... | An aromatase inhibitor that produces a state of "medical" adrenalectomy by blocking the production of adrenal steroids. It also blocks the conversion of androgens to estrogens. Aminoglutethimide has been used in the treatment of advanced breast and prostate cancer. It was formerly used for its weak anticonvulsant prope... | Moderate | 1 | [
[
[
1131,
24,
1051
]
],
[
[
1131,
21,
28921
],
[
28921,
60,
1051
]
],
[
[
1131,
24,
1101
],
[
1101,
23,
1051
]
],
[
[
1131,
24,
578
],
[
5... | [
[
[
"Methysergide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aminoglutethimide"
]
],
[
[
"Methysergide",
"{u} (Compound) causes {v} (Side Effect)",
"Dizziness"
],
[
"Dizziness",
"{u} (Side Effe... | Methysergide (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Aminoglutethimide (Compound)
Methysergide may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken wit... |
DB00690 | DB01142 | 1,216 | 1,264 | [
"DDInter762",
"DDInter593"
] | Flurazepam | Doxepin | A benzodiazepine derivative used mainly as a hypnotic. | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Moderate | 1 | [
[
[
1216,
24,
1264
]
],
[
[
1216,
24,
401
],
[
401,
24,
1264
]
],
[
[
1216,
63,
1594
],
[
1594,
24,
1264
]
],
[
[
1216,
24,
649
],
[
649,
... | [
[
[
"Flurazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Flurazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
... | Flurazepam may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Flurazepam may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxyl... |
DB00431 | DB01400 | 1,503 | 1,372 | [
"DDInter1072",
"DDInter1279"
] | Lindane | Neostigmine | An organochlorine insecticide that has been used as a pediculicide and a scabicide. Lindane has been banned in California, United Kingdom, Australia, and many western countries due to concerns about neurotoxicity and adverse effects on the environment. In Canada, Lindane is not recommmended as a first-line therapy due ... | A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike physostigmine, does not cross the blood-brain barrier. | Moderate | 1 | [
[
[
1503,
24,
1372
]
],
[
[
1503,
21,
28787
],
[
28787,
60,
1372
]
],
[
[
1503,
24,
1383
],
[
1383,
63,
1372
]
],
[
[
1503,
24,
1528
],
[
... | [
[
[
"Lindane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neostigmine"
]
],
[
[
"Lindane",
"{u} (Compound) causes {v} (Side Effect)",
"Dermatitis"
],
[
"Dermatitis",
"{u} (Side Effect) is caused ... | Lindane (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Neostigmine (Compound)
Lindane may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate and Sodium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Ne... |
DB00231 | DB00341 | 1,174 | 1,242 | [
"DDInter1761",
"DDInter343"
] | Temazepam | Cetirizine | Temazepam, like many other similar and related benzodiazepines, acts as a gamma-aminobutyric acid (GABA) modulator and is capable of eliciting a variety of actions including sedation, hypnosis, skeletal muscle relaxation, anticonvulsant activity, and anxiolytic action [A175207, A175210, F3718, F3721]. Although the chem... | Cetirizine, also commonly known as _Zyrtec_, is an orally active second-generation histamine H1 antagonist proven effective in the treatment of various allergic symptoms, such as sneezing, coughing, nasal congestion, hives, and other symptoms , . One of the most common uses for this drug is for a condition called _alle... | Moderate | 1 | [
[
[
1174,
24,
1242
]
],
[
[
1174,
24,
537
],
[
537,
63,
1242
]
],
[
[
1174,
21,
29027
],
[
29027,
60,
1242
]
],
[
[
1174,
23,
1031
],
[
10... | [
[
[
"Temazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cetirizine"
]
],
[
[
"Temazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclizine"
],
[
... | Temazepam may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine
Temazepam (Compound) causes Ataxia (Side Effect) and Ataxia (Side Effect) is caused by Cetirizine (Compound)
Temaze... |
DB01268 | DB08870 | 1,151 | 850 | [
"DDInter1731",
"DDInter228"
] | Sunitinib | Brentuximab vedotin | Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally av... | Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved... | Moderate | 1 | [
[
[
1151,
24,
850
]
],
[
[
1151,
63,
1570
],
[
1570,
24,
850
]
],
[
[
1151,
24,
1155
],
[
1155,
63,
850
]
],
[
[
1151,
64,
762
],
[
762,
... | [
[
[
"Sunitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Sunitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azithromycin"
],... | Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Azithromycin and Azithromycin may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Tucatinib ... |
DB00358 | DB00489 | 1,010 | 17 | [
"DDInter1140",
"DDInter1704"
] | Mefloquine | Sotalol | Malaria is a protozoan disease that places an enormous burden on human health in endemic areas around the world. The 2020 World Health Organization malaria report indicates a 60% decrease in the global malaria fatality rate between 2000 to 2019. Despite this, malaria remains a significant cause of morbidity and mortali... | Sotalol is a methanesulfonanilide developed in 1960. It was the first of the class III anti arrhythmic drugs. Sotalol was first approved as an oral tablet on 30 October 1992. A racemic mixture of sotalol is currently formulated as a tablet, oral solution, and intravenous injection indicated for life threatening ventric... | Major | 2 | [
[
[
1010,
25,
17
]
],
[
[
1010,
64,
347
],
[
347,
40,
17
]
],
[
[
1010,
63,
88
],
[
88,
40,
17
]
],
[
[
1010,
21,
28882
],
[
28882,
... | [
[
[
"Mefloquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sotalol"
]
],
[
[
"Mefloquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ibutilide"
],
[
"Ibutilide",
"{u} (Compo... | Mefloquine may lead to a major life threatening interaction when taken with Ibutilide and Ibutilide (Compound) resembles Sotalol (Compound)
Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Metoprolol and Metoprolol (Compound) resembles Sotalol (Compound)
Mefloquine (Compound) c... |
DB00207 | DB06589 | 1,570 | 1,250 | [
"DDInter157",
"DDInter1400"
] | Azithromycin | Pazopanib | Azithromycin is a broad-spectrum macrolide antibiotic with a long half-life and a high degree of tissue penetration. It was initially approved by the FDA in 1991. It is primarily used for the treatment of respiratory, enteric and genitourinary infections and may be used instead of other macrolides for some sexually tra... | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Major | 2 | [
[
[
1570,
25,
1250
]
],
[
[
1570,
6,
7950
],
[
7950,
45,
1250
]
],
[
[
1570,
18,
4187
],
[
4187,
46,
1250
]
],
[
[
1570,
7,
17513
],
[
175... | [
[
[
"Azithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pazopanib"
]
],
[
[
"Azithromycin",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
"Pazo... | Azithromycin (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Pazopanib (Compound)
Azithromycin (Compound) downregulates EIF4EBP1 (Gene) and EIF4EBP1 (Gene) is upregulated by Pazopanib (Compound)
Azithromycin (Compound) upregulates SLC35A1 (Gene) and SLC35A1 (Gene) is downregulated by Pazopanib (Compound)
A... |
DB00818 | DB00889 | 898 | 1,133 | [
"DDInter1538",
"DDInter840"
] | Propofol | Granisetron | Propofol is an intravenous anaesthetic agent used for induction and maintenance of general anaesthesia. IV administration of propfol is used to induce unconsciousness after which anaesthesia may be maintained using a combination of medications. Recovery from propofol-induced anaesthesia is generally rapid and associate... | A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic and antinauseant for cancer chemotherapy patients. | Moderate | 1 | [
[
[
898,
24,
1133
]
],
[
[
898,
6,
8374
],
[
8374,
45,
1133
]
],
[
[
898,
21,
29282
],
[
29282,
60,
1133
]
],
[
[
898,
23,
112
],
[
112,
... | [
[
[
"Propofol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Granisetron"
]
],
[
[
"Propofol",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Propofol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Granisetron (Compound)
Propofol (Compound) causes Arrhythmia (Side Effect) and Arrhythmia (Side Effect) is caused by Granisetron (Compound)
Propofol may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metro... |
DB00983 | DB01267 | 480 | 519 | [
"DDInter776",
"DDInter1381"
] | Formoterol | Paliperidone | Formoterol is an inhaled beta<sub>2</sub>-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001. It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers. A major ... | Paliperidone is the primary active metabolite of risperidone. The mechanism of action is unknown but it is likely to act via a similar pathway to risperidone. It has been proposed that the drug's therapeutic activity in schizophrenia is mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2... | Moderate | 1 | [
[
[
480,
24,
519
]
],
[
[
480,
63,
1664
],
[
1664,
1,
519
]
],
[
[
480,
24,
924
],
[
924,
1,
519
]
],
[
[
480,
6,
12523
],
[
12523,
... | [
[
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paliperidone"
]
],
[
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Risperidone"
],
[... | Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Risperidone and Risperidone (Compound) resembles Paliperidone (Compound)
Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Iloperidone and Iloperidone (Compound) resembles Paliperidone (Co... |
DB09330 | DB12332 | 985 | 1,619 | [
"DDInter1352",
"DDInter1626"
] | Osimertinib | Rucaparib | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the ... | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Major | 2 | [
[
[
985,
25,
1619
]
],
[
[
985,
63,
307
],
[
307,
23,
1619
]
],
[
[
985,
62,
112
],
[
112,
23,
1619
]
],
[
[
985,
63,
259
],
[
259,
... | [
[
[
"Osimertinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rucaparib"
]
],
[
[
"Osimertinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Modafinil"
],
[
"Modafinil"... | Osimertinib may cause a moderate interaction that could exacerbate diseases when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Osimertinib may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronid... |
DB00694 | DB06663 | 51 | 1,154 | [
"DDInter486",
"DDInter1398"
] | Daunorubicin (liposomal) | Pasireotide | Daunomycin can cause cancer according to an independent committee of scientific and health experts. | Pasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease. | Major | 2 | [
[
[
51,
25,
1154
]
],
[
[
51,
21,
28900
],
[
28900,
60,
1154
]
],
[
[
51,
23,
112
],
[
112,
23,
1154
]
],
[
[
51,
24,
466
],
[
466,
... | [
[
[
"Daunorubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pasireotide"
]
],
[
[
"Daunorubicin",
"{u} (Compound) causes {v} (Side Effect)",
"Abdominal pain"
],
[
"Abdominal pain",
"{u} (Side Effect) is caus... | Daunorubicin may lead to a major life threatening interaction when taken with Pasireotide
Daunorubicin (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Pasireotide (Compound)
Daunorubicin may cause a minor interaction that can limit clinical effects when taken with Metronidaz... |
DB00283 | DB01068 | 701 | 1,565 | [
"DDInter395",
"DDInter411"
] | Clemastine | Clonazepam | An ethanolamine-derivative, first generation histamine H1 antagonist used in hay fever, rhinitis, allergic skin conditions, and pruritus. It causes drowsiness. | A benzodiazepine used to treat various seizures, including myotonic or atonic seizures, photosensitive epilepsy, and absence seizures, although tolerance may develop.[FDA Label][L5572,F3763,F3787,F3796] The agent has also been indicated for treating panic disorder.[FDA Label][A175438,L5572,F3763,F3787,F3796] The mechan... | Moderate | 1 | [
[
[
701,
24,
1565
]
],
[
[
701,
24,
1382
],
[
1382,
1,
1565
]
],
[
[
701,
24,
1216
],
[
1216,
40,
1565
]
],
[
[
701,
63,
905
],
[
905,
... | [
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clonazepam"
]
],
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midazolam"
],
[
... | Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Midazolam and Midazolam (Compound) resembles Clonazepam (Compound)
Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Flurazepam and Flurazepam (Compound) resembles Clonazepam (Compound)
Cl... |
DB00951 | DB06595 | 1,072 | 1,491 | [
"DDInter986",
"DDInter1214"
] | Isoniazid | Midostaurin | Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis. | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hem... | Moderate | 1 | [
[
[
1072,
24,
1491
]
],
[
[
1072,
23,
1135
],
[
1135,
62,
1491
]
],
[
[
1072,
63,
112
],
[
112,
23,
1491
]
],
[
[
1072,
24,
761
],
[
761,
... | [
[
[
"Isoniazid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
]
],
[
[
"Isoniazid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
... | Isoniazid may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Midostaurin
Isoniazid may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidaz... |
DB00191 | DB04896 | 73 | 901 | [
"DDInter1447",
"DDInter1220"
] | Phentermine | Milnacipran | Phentermine is a sympathomimetic amine anorectic agent and it was introduced in 1959 as part of an anti-obesity combination drug.[A174361, A174364] It is chemically related to amphetamine and it is commonly referred to as an atypical amphetamine. Phentermine has not been reported an addictive potential which allows thi... | Milnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) and like many agents in this category was originally developed for and continues to be approved and indicated for the treatment of depression [F3928, F3934, A175786, A175951]. Furthermore, in 2009 the US FDA approved milnacipran for the a... | Major | 2 | [
[
[
73,
25,
901
]
],
[
[
73,
25,
41
],
[
41,
1,
901
]
],
[
[
73,
24,
1349
],
[
1349,
40,
901
]
],
[
[
73,
6,
6112
],
[
6112,
45,
... | [
[
[
"Phentermine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Milnacipran"
]
],
[
[
"Phentermine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Levomilnacipran"
],
[
"Levomilnacipran",... | Phentermine may lead to a major life threatening interaction when taken with Levomilnacipran and Levomilnacipran (Compound) resembles Milnacipran (Compound)
Phentermine may cause a moderate interaction that could exacerbate diseases when taken with Meperidine and Meperidine (Compound) resembles Milnacipran (Compound)
P... |
DB00853 | DB05679 | 1,686 | 1,683 | [
"DDInter1762",
"DDInter1907"
] | Temozolomide | Ustekinumab | Refractory anaplastic astrocytoma (WHO grade III) and Glioblastoma multiforme (WHO grade IV) are primary malignant brain tumours with poor prognosis and limited treatment options. Despite considerable genetic heterogeneity, these tumours often have impaired DNA repair systems, rendering them initially sensitive to alky... | Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses. It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. It is a targeted biologic dise... | Moderate | 1 | [
[
[
1686,
24,
1683
]
],
[
[
1686,
63,
1461
],
[
1461,
23,
1683
]
],
[
[
1686,
24,
1362
],
[
1362,
63,
1683
]
],
[
[
1686,
63,
305
],
[
305... | [
[
[
"Temozolomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
]
],
[
[
"Temozolomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
... | Temozolomide may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Ustekinumab
Temozolomide may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olapari... |
DB00472 | DB00574 | 758 | 121 | [
"DDInter758",
"DDInter717"
] | Fluoxetine | Fenfluramine | Fluoxetine is a 2nd generation antidepressant categorized as a selective serotonin reuptake inhibitor (SSRI). It gained FDA approval in 1987 and although it was initially intended for the treatment of depression, today it is commonly prescribed to manage depression in addition to various other pathologies. | Dravet syndrome is a pediatric encephalopathy that typically manifests within the first year of life following exposure to elevated temperatures. It is characterized by recurrent pharmacoresistant seizures, which increase in frequency and severity with disease progression. Concomitantly with these seizures, patients ty... | Major | 2 | [
[
[
758,
25,
121
]
],
[
[
758,
25,
1670
],
[
1670,
63,
121
]
],
[
[
758,
24,
1144
],
[
1144,
63,
121
]
],
[
[
758,
63,
366
],
[
366,
... | [
[
[
"Fluoxetine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fenfluramine"
]
],
[
[
"Fluoxetine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eliglustat"
],
[
"Eliglustat",
"{u}... | Fluoxetine may lead to a major life threatening interaction when taken with Eliglustat and Eliglustat may cause a moderate interaction that could exacerbate diseases when taken with Fenfluramine
Fluoxetine may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may ca... |
DB01162 | DB01216 | 195 | 284 | [
"DDInter1767",
"DDInter736"
] | Terazosin | Finasteride | Terazosin is a quinazoline derivative alpha-1-selective adrenergic blocking agent indicated for benign prostatic hyperplasia and hypertension[FDA Label]. Terazosin blocks adrenaline's action on alpha-1 adrenergic receptors, causing relaxation of smooth muscle in blood vessels and the prostate. | Finasteride is a synthetic 4-azasteroid compound and specific inhibitor of steroid Type II 5α-reductase, which is an intracellular enzyme that converts the androgen testosterone into 5α-dihydrotestosterone (DHT). It works in a similar fashion as [dutasteride], which is another 5-alpha-reductase inhibitor, by exerting a... | Minor | 0 | [
[
[
195,
23,
284
]
],
[
[
195,
21,
29247
],
[
29247,
60,
284
]
],
[
[
195,
21,
29247
],
[
29247,
60,
989
],
[
989,
1,
284
]
],
[
[
195,
... | [
[
[
"Terazosin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Finasteride"
]
],
[
[
"Terazosin",
"{u} (Compound) causes {v} (Side Effect)",
"Pharyngitis"
],
[
"Pharyngitis",
"{u} (Side Effect) is cau... | Terazosin (Compound) causes Pharyngitis (Side Effect) and Pharyngitis (Side Effect) is caused by Finasteride (Compound)
Terazosin (Compound) causes Pharyngitis (Side Effect) and Pharyngitis (Side Effect) is caused by Progesterone (Compound) and Progesterone (Compound) resembles Finasteride (Compound)
Terazosin (Compoun... |
DB12500 | DB12674 | 283 | 975 | [
"DDInter714",
"DDInter1105"
] | Fedratinib | Lurbinectedin | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Lurbinectedin is a DNA alkylating agent that has been investigated in the treatment of a variety of cancers, including mesothelioma, chronic lymphocytic leukemia (CLL), breast cancer, and small-cell lung cancer (SCLC). It is a derivative of the marine-derived agent ecteinascidin ([trabectedin]), an anticancer agent fou... | Major | 2 | [
[
[
283,
25,
975
]
],
[
[
283,
63,
1613
],
[
1613,
24,
975
]
],
[
[
283,
24,
159
],
[
159,
63,
975
]
],
[
[
283,
64,
1478
],
[
1478,
... | [
[
[
"Fedratinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lurbinectedin"
]
],
[
[
"Fedratinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
],
[
... | Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a and Peginterferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Lurbinectedin
Fedratinib may cause a moderate interaction that could exacerbate diseases when taken w... |
DB00370 | DB00719 | 1,251 | 1,219 | [
"DDInter1230",
"DDInter149"
] | Mirtazapine | Azatadine | Mirtazapine is a tetracyclic _piperazino-azepine_ antidepressant agent that was initially approved for the treatment of major depressive disorder (MDD) in the Netherlands in 1994. This drug was first manufactured by Organon Inc., and received FDA approval in 1997 for the treatment of major depressive disorder.[T595, L6... | Antihistamines such as azatadine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine which are mediated through activation of H1- receptor sites and thereby reduce the intensity of allergic reactions and tissue inj... | Moderate | 1 | [
[
[
1251,
35,
1219
]
],
[
[
1251,
40,
11287
],
[
11287,
1,
1219
]
],
[
[
1251,
24,
13
],
[
13,
24,
1219
]
],
[
[
1251,
1,
830
],
[
830,
... | [
[
[
"Mirtazapine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azatadine"
]
],
[
[
"Mirtazapine",
"{u} (Compound) resembles {v} (Compound)",
"Pirenzepine"
],
[
... | Mirtazapine (Compound) resembles Azatadine (Compound) and
Mirtazapine (Compound) resembles Pirenzepine (Compound) and Pirenzepine (Compound) resembles Azatadine (Compound)
Mirtazapine may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine may cause a moderate i... |
DB00741 | DB01276 | 167 | 123 | [
"DDInter885",
"DDInter706"
] | Hydrocortisone | Exenatide | Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone wa... | Exenatide is a glucagon-like peptide-1 (GLP-1) analog. It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control. Exenatide was given FDA approval on April 28, 2005. It is available as immediate- and extended-release formulation... | Moderate | 1 | [
[
[
167,
24,
123
]
],
[
[
167,
63,
1252
],
[
1252,
23,
123
]
],
[
[
167,
23,
1072
],
[
1072,
24,
123
]
],
[
[
167,
63,
380
],
[
380,
... | [
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
]
],
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digoxin"
],
... | Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Digoxin and Digoxin may cause a minor interaction that can limit clinical effects when taken with Exenatide
Hydrocortisone may cause a minor interaction that can limit clinical effects when taken with Isoniazid and Isoniazid ... |
DB00176 | DB09272 | 529 | 412 | [
"DDInter770",
"DDInter632"
] | Fluvoxamine | Eluxadoline | Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database ... | Eluxadoline is a mixed mu-opioid receptor agonist, kappa-opioid receptor agonist, and a-delta opioid receptor antagonist indicated for use in diarrhea-predominant irritable bowel syndrome (IBS-D). The mu-, kappa-, and delta-opioid receptors mediate endogenous and exogenous opioid response in the central nervous system ... | Moderate | 1 | [
[
[
529,
24,
412
]
],
[
[
529,
24,
1594
],
[
1594,
24,
412
]
],
[
[
529,
25,
1347
],
[
1347,
24,
412
]
],
[
[
529,
24,
407
],
[
407,
... | [
[
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eluxadoline"
]
],
[
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[... | Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline
Fluvoxamine may lead to a major life threatening interaction when taken with Clopidogrel and Clopidogrel may c... |
DB01183 | DB01192 | 173 | 560 | [
"DDInter1262",
"DDInter1372"
] | Naloxone | Oxymorphone | Naloxone is an opioid antagonist medication used to block or reverse the effects of opioid drugs, particularly within the setting of drug overdoses which are rapidly becoming a leading cause of death worldwide. More specifically, naloxone has a high affinity for μ-opioid receptors, where it acts as an inverse agonist, ... | An opioid analgesic with actions and uses similar to those of morphine, apart from an absence of cough suppressant activity. It is used in the treatment of moderate to severe pain, including pain in obstetrics. It may also be used as an adjunct to anesthesia (From Martindale, The Extra Pharmacopoeia, 30th ed, p1092). O... | Moderate | 1 | [
[
[
173,
35,
560
]
],
[
[
173,
1,
509
],
[
509,
1,
560
]
],
[
[
173,
63,
828
],
[
828,
1,
560
]
],
[
[
173,
35,
1159
],
[
1159,
40,
... | [
[
[
"Naloxone",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxymorphone"
]
],
[
[
"Naloxone",
"{u} (Compound) resembles {v} (Compound)",
"Buprenorphine"
],
[
... | Naloxone (Compound) resembles Oxymorphone (Compound) and
Naloxone (Compound) resembles Buprenorphine (Compound) and Buprenorphine (Compound) resembles Oxymorphone (Compound)
Naloxone may cause a moderate interaction that could exacerbate diseases when taken with Oxycodone and Oxycodone (Compound) resembles Oxymorphone ... |
DB11718 | DB12015 | 927 | 1,033 | [
"DDInter640",
"DDInter53"
] | Encorafenib | Alpelisib | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... | Alpelisib is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potent antitumor activity. It works by selectively inhibiting class I PI3K p110α , which is the catalytic subunit of PI3K, a lipid kinase that plays a role in various biological processes, including proliferation, survival, differentiation, and metaboli... | Moderate | 1 | [
[
[
927,
24,
1033
]
],
[
[
927,
63,
1135
],
[
1135,
23,
1033
]
],
[
[
927,
64,
576
],
[
576,
24,
1033
]
],
[
[
927,
24,
738
],
[
738,
... | [
[
[
"Encorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Encorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxegol"
],
[
... | Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Alpelisib
Encorafenib may lead to a major life threatening interaction when taken with Methadone and Methadone may cause a mod... |
DB01253 | DB01259 | 628 | 392 | [
"DDInter664",
"DDInter1024"
] | Ergometrine | Lapatinib | An ergot alkaloid with uterine and vascular smooth muscle contractile properties. | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epide... | Moderate | 1 | [
[
[
628,
24,
392
]
],
[
[
628,
6,
4973
],
[
4973,
45,
392
]
],
[
[
628,
7,
3727
],
[
3727,
46,
392
]
],
[
[
628,
21,
28695
],
[
28695,
... | [
[
[
"Ergometrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
]
],
[
[
"Ergometrine",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Ergometrine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Lapatinib (Compound)
Ergometrine (Compound) upregulates MAL (Gene) and MAL (Gene) is upregulated by Lapatinib (Compound)
Ergometrine (Compound) causes Dyspnoea (Side Effect) and Dyspnoea (Side Effect) is caused by Lapatinib (Compound)
Ergometrine ma... |
DB05015 | DB08903 | 1,077 | 996 | [
"DDInter174",
"DDInter170"
] | Belinostat | Bedaquiline | Belinostat is a novel agent that inhibits the enzyme histone deacetylase (HDAC) with a sulfonamide-hydroxamide structure. It was developed as an orphan drug to target hematological malignancies and solid tumors by TopoTarget. The safety and efficacy of belinostat is currently being evaluated for use in combination with... | Bedaquiline is a bactericidal antimycobacterial drug belonging to the class of diarylquinoline. The quinolinic central heterocyclic nucleus with alcohol and amine side chains is responsible for bedaquiline-mediated antimycobacterial activity. Although it is closely related to fluoroquinolones, bedaquiline does not affe... | Moderate | 1 | [
[
[
1077,
24,
996
]
],
[
[
1077,
24,
713
],
[
713,
63,
996
]
],
[
[
1077,
63,
372
],
[
372,
24,
996
]
],
[
[
1077,
24,
292
],
[
292,
... | [
[
[
"Belinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bedaquiline"
]
],
[
[
"Belinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dimethyl fumarate"
],
... | Belinostat may cause a moderate interaction that could exacerbate diseases when taken with Dimethyl fumarate and Dimethyl fumarate may cause a moderate interaction that could exacerbate diseases when taken with Bedaquiline
Belinostat may cause a moderate interaction that could exacerbate diseases when taken with Clofar... |
DB00635 | DB00912 | 1,573 | 473 | [
"DDInter1515",
"DDInter1581"
] | Prednisone | Repaglinide | A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955. | Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response... | Moderate | 1 | [
[
[
1573,
24,
473
]
],
[
[
1573,
6,
1829
],
[
1829,
45,
473
]
],
[
[
1573,
21,
28873
],
[
28873,
60,
473
]
],
[
[
1573,
40,
1103
],
[
1103... | [
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Repaglinide"
]
],
[
[
"Prednisone",
"{u} (Compound) binds {v} (Gene)",
"ALB"
],
[
"ALB",
"{u} (Gene) is bound by {v} (Compound)",
... | Prednisone (Compound) binds ALB (Gene) and ALB (Gene) is bound by Repaglinide (Compound)
Prednisone (Compound) causes Pancreatitis (Side Effect) and Pancreatitis (Side Effect) is caused by Repaglinide (Compound)
Prednisone (Compound) resembles Amcinonide (Compound) and Amcinonide may cause a minor interaction that can ... |
DB00722 | DB01156 | 743 | 593 | [
"DDInter1079",
"DDInter252"
] | Lisinopril | Bupropion | Lisinopril is an angiotensin converting enzyme inhibitor (ACEI) used to treat hypertension, heart failure, and myocardial infarction.[L8384,L8387,L8390] Lisinopril and [captopril] are the only ACEIs that are not prodrugs. It functions by inhibition of angiotensin converting enzyme as well as the renin angiotensin aldos... | Bupropion (also known as the brand name product Wellbutrin®) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid for smoking cessation. Bupropion exerts its pharmacological effects by weakly inh... | Moderate | 1 | [
[
[
743,
24,
593
]
],
[
[
743,
21,
29243
],
[
29243,
60,
593
]
],
[
[
743,
63,
322
],
[
322,
24,
593
]
],
[
[
743,
40,
1638
],
[
1638,
... | [
[
[
"Lisinopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bupropion"
]
],
[
[
"Lisinopril",
"{u} (Compound) causes {v} (Side Effect)",
"Wheezing"
],
[
"Wheezing",
"{u} (Side Effect) is caused ... | Lisinopril (Compound) causes Wheezing (Side Effect) and Wheezing (Side Effect) is caused by Bupropion (Compound)
Lisinopril may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Bupropion
... |
DB00719 | DB01148 | 1,219 | 1,128 | [
"DDInter149",
"DDInter738"
] | Azatadine | Flavoxate | Antihistamines such as azatadine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine which are mediated through activation of H1- receptor sites and thereby reduce the intensity of allergic reactions and tissue inj... | A drug that has been used in various urinary syndromes and as an antispasmodic. Its therapeutic usefulness and its mechanism of action are not clear. It may have local anesthetic activity and direct relaxing effects on smooth muscle as well as some activity as a muscarinic antagonist. [PubChem] | Moderate | 1 | [
[
[
1219,
24,
1128
]
],
[
[
1219,
24,
1123
],
[
1123,
24,
1128
]
],
[
[
1219,
24,
1511
],
[
1511,
63,
1128
]
],
[
[
1219,
63,
506
],
[
506... | [
[
[
"Azatadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flavoxate"
]
],
[
[
"Azatadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propantheline"
],
[
... | Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Propantheline and Propantheline may cause a moderate interaction that could exacerbate diseases when taken with Flavoxate
Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Me... |
DB00518 | DB11988 | 510 | 270 | [
"DDInter35",
"DDInter1321"
] | Albendazole | Ocrelizumab | A benzimidazole broad-spectrum anthelmintic structurally related to mebendazole that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38) | Ocrelizumab is a CD20-directed cytolytic antibody indicated for the treatment of patients with primary progressive or relapsing forms of multiple sclerosis (MS). It is a second-generation recombinant humanized monoclonal IgG1 antibody that selectively targets B-cells that express the CD20 antigen. Compared to non-human... | Moderate | 1 | [
[
[
510,
24,
270
]
],
[
[
510,
24,
800
],
[
800,
24,
270
]
],
[
[
510,
63,
1101
],
[
1101,
24,
270
]
],
[
[
510,
24,
1619
],
[
1619,
... | [
[
[
"Albendazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Albendazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Duvelisib"
],
[
... | Albendazole may cause a moderate interaction that could exacerbate diseases when taken with Duvelisib and Duvelisib may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab
Albendazole may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexar... |
DB00938 | DB01365 | 455 | 280 | [
"DDInter1635",
"DDInter1151"
] | Salmeterol | Mephentermine | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salm... | A sympathomimetic agent with mainly indirect effects on adrenergic receptors. It is used to maintain blood pressure in hypotensive states, for example, following spinal anesthesia. Although the central stimulant effects of mephentermine are much less than those of amphetamine, its use may lead to amphetamine-type depen... | Moderate | 1 | [
[
[
455,
24,
280
]
],
[
[
455,
63,
551
],
[
551,
1,
280
]
],
[
[
455,
63,
80
],
[
80,
40,
280
]
],
[
[
455,
24,
1161
],
[
1161,
1,
... | [
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mephentermine"
]
],
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenelzine"
],
[... | Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Phenelzine and Phenelzine (Compound) resembles Mephentermine (Compound)
Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Amphetamine and Amphetamine (Compound) resembles Mephentermine (Co... |
DB00549 | DB01095 | 522 | 671 | [
"DDInter1955",
"DDInter769"
] | Zafirlukast | Fluvastatin | Zafirlukast is an oral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma, often used in conjunction with an inhaled steroid and/or long-acting bronchodilator. It is available as a tablet and is usually dosed twice daily. Another leukotriene receptor antagonist is montelukast (Singulair), wh... | Fluvastatin is an antilipemic agent that competitively inhibits hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase. HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in cholesterol biosynthesis. Fluvastatin belongs to a class of medications called statins and is used to r... | Moderate | 1 | [
[
[
522,
24,
671
]
],
[
[
522,
24,
788
],
[
788,
40,
671
]
],
[
[
522,
24,
14
],
[
14,
63,
671
]
],
[
[
522,
6,
7950
],
[
7950,
45,
... | [
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvastatin"
]
],
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitavastatin"
],
... | Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Pitavastatin and Pitavastatin (Compound) resembles Fluvastatin (Compound)
Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Rosuvastatin and Rosuvastatin may cause a moderate interaction... |
DB00357 | DB11652 | 1,051 | 1,155 | [
"DDInter71",
"DDInter1891"
] | Aminoglutethimide | Tucatinib | An aromatase inhibitor that produces a state of "medical" adrenalectomy by blocking the production of adrenal steroids. It also blocks the conversion of androgens to estrogens. Aminoglutethimide has been used in the treatment of advanced breast and prostate cancer. It was formerly used for its weak anticonvulsant prope... | Tucatinib is a kinase inhibitor drug used with [trastuzumab] and [capecitabine] in the treatment of unresectable or metastatic HER-2 positive breast cancer. It was developed by Seattle Genetics and approved by the FDA on April 17, 2020. Tucatinib is a promising new treatment for patients with metastatic breast cancer w... | Moderate | 1 | [
[
[
1051,
24,
1155
]
],
[
[
1051,
62,
1101
],
[
1101,
23,
1155
]
],
[
[
1051,
24,
1424
],
[
1424,
24,
1155
]
],
[
[
1051,
24,
466
],
[
466... | [
[
[
"Aminoglutethimide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tucatinib"
]
],
[
[
"Aminoglutethimide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
... | Aminoglutethimide may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Tucatinib
Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Quinine and ... |
DB00396 | DB11967 | 989 | 710 | [
"DDInter1529",
"DDInter210"
] | Progesterone | Binimetinib | Progesterone is a hormone that occurs naturally in females, and is essential for endometrial receptivity, embryo implantation, and the successful establishment of pregnancy. A low progesterone concentration or an insufficient response to progesterone can cause infertility and pregnancy loss. Progesterone is used in var... | Binimetinib, also known as _Mektovi_, is a potent and selective oral mitogen-activated protein kinase 1/2 (MEK 1/2) inhibitor which is combined with [Encorafenib].[A34275,L3335] On June 27, 2018, the Food and Drug Administration approved the combination of [Encorafenib] and binimetinib (BRAFTOVI and MEKTOVI, from Array... | Moderate | 1 | [
[
[
989,
24,
710
]
],
[
[
989,
24,
1619
],
[
1619,
63,
710
]
],
[
[
989,
24,
129
],
[
129,
24,
710
]
],
[
[
989,
1,
443
],
[
443,
24... | [
[
[
"Progesterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Binimetinib"
]
],
[
[
"Progesterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
... | Progesterone may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Progesterone may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and E... |
DB01601 | DB11363 | 833 | 1,276 | [
"DDInter1089",
"DDInter39"
] | Lopinavir | Alectinib | Lopinavir is an antiretroviral protease inhibitor used in combination with other antiretrovirals in the treatment of HIV-1 infection. Lopinavir is marketed and administered exclusively in combination with [ritonavir] - this combination, first marketed by Abbott under the brand name Kaletra in 2000, is necessary due to ... | Alectinib is a second generation oral drug that selectively inhibits the activity of anaplastic lymphoma kinase (ALK) tyrosine kinase. It is specifically used in the treatment of non-small cell lung cancer (NSCLC) expressing the ALK-EML4 (echinoderm microtubule-associated protein-like 4) fusion protein that causes prol... | Moderate | 1 | [
[
[
833,
24,
1276
]
],
[
[
833,
25,
1011
],
[
1011,
24,
1276
]
],
[
[
833,
63,
1010
],
[
1010,
24,
1276
]
],
[
[
833,
64,
1166
],
[
1166,
... | [
[
[
"Lopinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alectinib"
]
],
[
[
"Lopinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
],
[
"Fingolimod",
... | Lopinavir may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Alectinib
Lopinavir may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine and Mefloquine may cause a m... |
DB00978 | DB06603 | 739 | 39 | [
"DDInter1084",
"DDInter1387"
] | Lomefloxacin | Panobinostat | Lomefloxacin is a fluoroquinolone antibiotic, used to treat bacterial infections including bronchitis and urinary tract infections (UTIs). Additionally, it has been employed for the prophylaxis of UTIs prior to surgery as well. | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress... | Major | 2 | [
[
[
739,
25,
39
]
],
[
[
739,
62,
112
],
[
112,
23,
39
]
],
[
[
739,
63,
455
],
[
455,
24,
39
]
],
[
[
739,
23,
869
],
[
869,
24,
... | [
[
[
"Lomefloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
]
],
[
[
"Lomefloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Met... | Lomefloxacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Panobinostat
Lomefloxacin may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol an... |
DB05773 | DB06802 | 1,047 | 282 | [
"DDInter1848",
"DDInter1280"
] | Trastuzumab emtansine | Nepafenac (ophthalmic) | Trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent, DM1. T-DM1 combines two strategies-- anti-HER2 activity and targeted intracellular delivery of the potent anti-mic... | Nepafenac is a monocarboxylic acid amide that is amfenac in which the carboxylic acid group has been converted into the corresponding carboxamide. It is a prodrug for amfenac, used in eye drops to treat pain and inflammation following cataract surgery. It has a role as a prodrug, a cyclooxygenase 2 inhibitor, a cycloox... | Moderate | 1 | [
[
[
1047,
24,
282
]
],
[
[
1047,
63,
886
],
[
886,
1,
282
]
],
[
[
1047,
25,
39
],
[
39,
24,
282
]
],
[
[
1047,
25,
1468
],
[
1468,
... | [
[
[
"Trastuzumab emtansine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nepafenac"
]
],
[
[
"Trastuzumab emtansine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ketoro... | Trastuzumab emtansine may cause a moderate interaction that could exacerbate diseases when taken with Nepafenac
Trastuzumab emtansine may cause a moderate interaction that could exacerbate diseases when taken with Ketorolac and Ketorolac (Compound) resembles Nepafenac (Compound)
Trastuzumab emtansine may lead to a majo... |
DB00361 | DB00743 | 134 | 808 | [
"DDInter1939",
"DDInter792"
] | Vinorelbine | Gadobenic acid | Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC). It was initially approved in the USA in 1990's for the treatment of NSCLC. It is a third-generation vinca alkaloid. The introduction of third-g... | Gadobenic acid, usually available in the salt form gadobenate dimeglumine, is a linear MRI gadolinium-based contrast agent (GBCA) used primarily for MR imaging of the liver. It differs from other GBCAs due to the benzene ring that confers weak protein binding, thus leading to an increased R1 and R2 relaxivity. As gadob... | Moderate | 1 | [
[
[
134,
24,
808
]
],
[
[
134,
21,
28769
],
[
28769,
60,
808
]
],
[
[
134,
64,
215
],
[
215,
24,
808
]
],
[
[
134,
25,
34
],
[
34,
6... | [
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gadobenic acid"
]
],
[
[
"Vinorelbine",
"{u} (Compound) causes {v} (Side Effect)",
"Feeling abnormal"
],
[
"Feeling abnormal",
"{u} (... | Vinorelbine (Compound) causes Feeling abnormal (Side Effect) and Feeling abnormal (Side Effect) is caused by Gadobenic acid (Compound)
Vinorelbine may lead to a major life threatening interaction when taken with Indinavir and Indinavir may cause a moderate interaction that could exacerbate diseases when taken with Gado... |
DB01156 | DB09074 | 593 | 1,362 | [
"DDInter252",
"DDInter1327"
] | Bupropion | Olaparib | Bupropion (also known as the brand name product Wellbutrin®) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid for smoking cessation. Bupropion exerts its pharmacological effects by weakly inh... | Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Ol... | Moderate | 1 | [
[
[
593,
24,
1362
]
],
[
[
593,
64,
576
],
[
576,
24,
1362
]
],
[
[
593,
25,
250
],
[
250,
24,
1362
]
],
[
[
593,
63,
450
],
[
450,
... | [
[
[
"Bupropion",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
]
],
[
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methadone"
],
[
"Methadone",
... | Bupropion may lead to a major life threatening interaction when taken with Methadone and Methadone may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Bupropion may lead to a major life threatening interaction when taken with Blinatumomab and Blinatumomab may cause a moderate intera... |
DB00022 | DB06317 | 268 | 1,626 | [
"DDInter1408",
"DDInter630"
] | Peginterferon alfa-2b | Elotuzumab | Peginterferon alfa-2b is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most co... | Elotuzumab is a humanized IgG1 (Immunoglobulin G) monoclonal antibody indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies. Elotuzumab targets SLAMF7, also known as Signaling Lymphocytic Activation Molecule Family... | Moderate | 1 | [
[
[
268,
24,
1626
]
],
[
[
268,
24,
973
],
[
973,
24,
1626
]
],
[
[
268,
24,
310
],
[
310,
63,
1626
]
],
[
[
268,
25,
1477
],
[
1477,
... | [
[
[
"Peginterferon alfa-2b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elotuzumab"
]
],
[
[
"Peginterferon alfa-2b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pacli... | Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Elotuzumab
Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with... |
DB04865 | DB08885 | 4 | 363 | [
"DDInter1335",
"DDInter33"
] | Omacetaxine mepesuccinate | Aflibercept | Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the pla... | Aflibercept is a recombinant protein composed of the binding domains of two human vascular endothelial growth factor (VEGF) receptors, VEGFR1 and VEGFR2, fused with the Fc region of human immunoglobulin gamma 1 (IgG1). Structurally, Aflibercept is a dimeric glycoprotein with a protein molecular weight of 96.9 kilo Dalt... | Moderate | 1 | [
[
[
4,
24,
363
]
],
[
[
4,
24,
1531
],
[
1531,
24,
363
]
],
[
[
4,
24,
151
],
[
151,
63,
363
]
],
[
[
4,
63,
58
],
[
58,
24,
3... | [
[
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aflibercept"
]
],
[
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
... | Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Aflibercept
Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when... |
DB00304 | DB08912 | 1,657 | 1,040 | [
"DDInter508",
"DDInter462"
] | Desogestrel | Dabrafenib | Desogestrel, a prodrug, is a third generation progestogen and hence, a member of the gonane family which was largely used in Europe before being approved in the US and Canada. It was firstly generated from a study that showed that 11-beta and 11-alkylidene substituent in nortestosterone can enhance the biological activ... | Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib... | Major | 2 | [
[
[
1657,
25,
1040
]
],
[
[
1657,
21,
28900
],
[
28900,
60,
1040
]
],
[
[
1657,
25,
1101
],
[
1101,
23,
1040
]
],
[
[
1657,
24,
1478
],
[
... | [
[
[
"Desogestrel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dabrafenib"
]
],
[
[
"Desogestrel",
"{u} (Compound) causes {v} (Side Effect)",
"Abdominal pain"
],
[
"Abdominal pain",
"{u} (Side Effect) is caused ... | Desogestrel (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Dabrafenib (Compound)
Desogestrel may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Dabrafenib
D... |
DB06210 | DB15982 | 72 | 1,339 | [
"DDInter631",
"DDInter193"
] | Eltrombopag | Berotralstat | Eltrombopag is used to treat low blood platelet counts in adults with chronic immune (idiopathic) thrombocytopenia (ITP), when certain other medicines, or surgery to remove the spleen, have not worked well enough. ITP is a condition that may cause unusual bruising or bleeding due to an abnormally low number of platelet... | Berotralstat is a selective inhibitor of plasma kallikrein used in the prophylaxis of attacks of hereditary angioedema (HAE). It works by blocking the enzymatic activity of plasma kallikrein in releasing bradykinin, the major biologic peptide that promotes swelling and pain associated with attacks of HAE. Berotralstat ... | Major | 2 | [
[
[
72,
25,
1339
]
],
[
[
72,
24,
119
],
[
119,
24,
1339
]
],
[
[
72,
63,
1413
],
[
1413,
24,
1339
]
],
[
[
72,
24,
1619
],
[
1619,
... | [
[
[
"Eltrombopag",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Berotralstat"
]
],
[
[
"Eltrombopag",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Talazoparib"
],
[
"Talaz... | Eltrombopag may cause a moderate interaction that could exacerbate diseases when taken with Talazoparib and Talazoparib may cause a moderate interaction that could exacerbate diseases when taken with Berotralstat
Eltrombopag may cause a moderate interaction that could exacerbate diseases when taken with Fexofenadine an... |
DB08899 | DB12095 | 129 | 179 | [
"DDInter649",
"DDInter1760"
] | Enzalutamide | Telotristat ethyl | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Telotristat ethyl is a prodrug of telotristat that was approved by the FDA in March 2017 as Xermelo. It was previously referred to as telotristat etiprate, the hippurate salt form; however, the FDA recommends the use of the name of the neutral form rather than that of the salt.[A252937, A252942] Currently, telotristat ... | Moderate | 1 | [
[
[
129,
24,
179
]
],
[
[
129,
63,
79
],
[
79,
24,
179
]
],
[
[
129,
64,
1493
],
[
1493,
24,
179
]
],
[
[
129,
25,
214
],
[
214,
24,... | [
[
[
"Enzalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telotristat ethyl"
]
],
[
[
"Enzalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sorafenib"
]... | Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Telotristat ethyl
Enzalutamide may lead to a major life threatening interaction when taken with Halofantrine and Halofantri... |
DB08946 | DB09133 | 512 | 1,527 | [
"DDInter962",
"DDInter965"
] | Iopanoic acid | Iothalamic acid | Iopanoic acid contains iodine and is useful as a contrast medium in cholecystography. | Iothalamic acid is an iodine containing organic anion used as a diagnostic contrast agent. | Moderate | 1 | [
[
[
512,
24,
1527
]
],
[
[
512,
63,
84
],
[
84,
24,
1527
]
],
[
[
512,
24,
1586
],
[
1586,
63,
1527
]
],
[
[
512,
63,
84
],
[
84,
24... | [
[
[
"Iopanoic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iothalamic acid"
]
],
[
[
"Iopanoic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nisoldipine"
... | Iopanoic acid may cause a moderate interaction that could exacerbate diseases when taken with Nisoldipine and Nisoldipine may cause a moderate interaction that could exacerbate diseases when taken with Iothalamic acid
Iopanoic acid may cause a moderate interaction that could exacerbate diseases when taken with Levamlod... |
DB11989 | DB12240 | 1,434 | 110 | [
"DDInter183",
"DDInter1485"
] | Benznidazole | Polatuzumab vedotin | Benznidazole was granted accelerated approval for the treatment of Chagas disease in children 2-12 years of age by the FDA on August 29, 2017. It is the first treatment made available in the United States for Chagas disease. | Polatuzumab vedotin is a CD79b-directed antibody-drug conjugate that delivers monomethyl auristatin E (MMAE), an anti-mitotic agent, to cancer cells. The drug consists of three components - a humanized immunoglobulin G1 (IgG1) monoclonal antibody specific for human CD79b (polatuzumab), MMAE, and protease-cleavable link... | Moderate | 1 | [
[
[
1434,
24,
110
]
],
[
[
1434,
63,
467
],
[
467,
24,
110
]
],
[
[
1434,
24,
148
],
[
148,
63,
110
]
],
[
[
1434,
63,
908
],
[
908,
... | [
[
[
"Benznidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Polatuzumab vedotin"
]
],
[
[
"Benznidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Simvastatin"
... | Benznidazole may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Polatuzumab vedotin
Benznidazole may cause a moderate interaction that could exacerbate diseases when taken with Secnid... |
DB00063 | DB00460 | 366 | 612 | [
"DDInter659",
"DDInter1929"
] | Eptifibatide | Verteporfin | Synthetic cyclic hexapeptide that binds to platelet receptor glycoprotein and inhibits platelet aggregation. Derived from venom of the Southeastern pygmy rattlesnake (Sistrurus miliarus barbouri), eptifibatide is a cyclic heptapeptide that belongs to the class of arginin-glycin-aspartat-mimetics. | Verteporfin, marketed as Visudyne, is a benzoporphyrin derivative. It is used as a photosensitizer in photodynamic therapy to eliminate abnormal blood vessels in wet form macular degeneration. Verteporfin accumulates in these abnormal blood vessels and, when stimulated by nonthermal red light with a wavelength of 693 n... | Moderate | 1 | [
[
[
366,
24,
612
]
],
[
[
366,
63,
942
],
[
942,
24,
612
]
],
[
[
366,
25,
936
],
[
936,
63,
612
]
],
[
[
366,
24,
1512
],
[
1512,
6... | [
[
[
"Eptifibatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Verteporfin"
]
],
[
[
"Eptifibatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bivalirudin"
],
... | Eptifibatide may cause a moderate interaction that could exacerbate diseases when taken with Bivalirudin and Bivalirudin may cause a moderate interaction that could exacerbate diseases when taken with Verteporfin
Eptifibatide may lead to a major life threatening interaction when taken with Cangrelor and Cangrelor may c... |
DB00798 | DB01416 | 1,132 | 1,024 | [
"DDInter815",
"DDInter326"
] | Gentamicin | Cefpodoxime | Gentamicin is a bactericidal aminoglycoside that was discovered and isolated from _Micromonospora purpurea_ in 1963. It is one of the most frequently prescribed aminoglycosides due to its spectrum of activity, low cost, and availability.[A234339,A234354] Gentamicin is effective against both gram-positive and gram-negat... | Cefpodoxime is an oral third generation cephalosporin antibiotic with effectiveness against most Gram positive and Gram negative bacteria. Commonly used to treat acute otitis media, pharyngitis, and sinusitis, cefpodoxime proxetil is a prodrug which is absorbed and de-esterified by the intestinal mucosa to Cefpodoxime. | Moderate | 1 | [
[
[
1132,
24,
1024
]
],
[
[
1132,
24,
1453
],
[
1453,
1,
1024
]
],
[
[
1132,
63,
149
],
[
149,
40,
1024
]
],
[
[
1132,
24,
665
],
[
665,
... | [
[
[
"Gentamicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefpodoxime"
]
],
[
[
"Gentamicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ceftriaxone"
],
[
... | Gentamicin may cause a moderate interaction that could exacerbate diseases when taken with Ceftriaxone and Ceftriaxone (Compound) resembles Cefpodoxime (Compound)
Gentamicin may cause a moderate interaction that could exacerbate diseases when taken with Ceftazidime and Ceftazidime (Compound) resembles Cefpodoxime (Comp... |
DB05679 | DB16582 | 1,683 | 899 | [
"DDInter1907",
"DDInter1080"
] | Ustekinumab | Lisocabtagene maraleucel | Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses. It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. It is a targeted biologic dise... | Lisocabtagene maraleucel is a chimeric antigen receptor (CAR) T-cell therapy, similar to [brexucabtagene autoleucel] and [axicabtagene ciloleucel].[A228493,L31588] Lisocabtagene maraleucel is a genetically modified autologous T-cell therapy that targets CD19, the B-lymphocyte surface antigen B4. CAR T-cell therapy has ... | Moderate | 1 | [
[
[
1683,
24,
899
]
],
[
[
1683,
63,
869
],
[
869,
24,
899
]
],
[
[
1683,
24,
1362
],
[
1362,
24,
899
]
],
[
[
1683,
25,
676
],
[
676,
... | [
[
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lisocabtagene maraleucel"
]
],
[
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
... | Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Lisocabtagene maraleucel
Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Olapari... |
DB00413 | DB00427 | 1,346 | 1,233 | [
"DDInter1505",
"DDInter1879"
] | Pramipexole | Triprolidine | Pramipexole is a drug used to treat the symptoms of Parkinson's Disease (PD). It is a _non-ergot dopamine agonist_ drug that is efficacious in treating various Parkinson's symptoms such as tremor, rigidity, and bradykinesia (slow movement). It was first approved by the FDA in 1997. Parkinson's Disease is one of the mos... | First generation histamine H1 antagonist used in allergic rhinitis; asthma; and urticaria. It is a component of cough and cold medicines. It may cause drowsiness. | Moderate | 1 | [
[
[
1346,
24,
1233
]
],
[
[
1346,
24,
104
],
[
104,
63,
1233
]
],
[
[
1346,
63,
1242
],
[
1242,
24,
1233
]
],
[
[
1346,
24,
104
],
[
104,
... | [
[
[
"Pramipexole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triprolidine"
]
],
[
[
"Pramipexole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
... | Pramipexole may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Triprolidine
Pramipexole may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine an... |
DB06636 | DB12500 | 1,623 | 283 | [
"DDInter980",
"DDInter714"
] | Isavuconazonium | Fedratinib | Isavuconazonium is a second-generation triazole antifungal approved on March 6, 2015 by the FDA and July 2015 by the EMA for the treatment of adults with invasive aspergillosis and invasive mucormycosis, marketed by Astellas under the brand Cresemba. It is the prodrug form of isavuconazole, the active moiety, and it is... | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Moderate | 1 | [
[
[
1623,
24,
283
]
],
[
[
1623,
23,
466
],
[
466,
62,
283
]
],
[
[
1623,
24,
351
],
[
351,
23,
283
]
],
[
[
1623,
63,
1419
],
[
1419,
... | [
[
[
"Isavuconazonium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Isavuconazonium",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Darolutamide"
]... | Isavuconazonium may cause a minor interaction that can limit clinical effects when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Isavuconazonium may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib ... |
DB00836 | DB11732 | 543 | 1,097 | [
"DDInter1088",
"DDInter1027"
] | Loperamide | Lasmiditan | Loperamide is an anti-diarrheal agent that is available as various over-the-counter products for treating diarrhea. The drug was first synthesized in 1969 and used medically in 1976. It is a highly lipophilic synthetic phenylpiperidine opioid that is structurally similar to opiate receptor agonists such as [diphenoxyla... | Lasmiditan is an oral medication used in the termination of migraine headaches that was first approved for use in the United States in October 2019.[L9338,L9356] It was also approved by the European Commission on August 17, 2022. Traditionally, the triptan class of anti-migraine medications (e.g. [sumatriptan]) have se... | Moderate | 1 | [
[
[
543,
24,
1097
]
],
[
[
543,
63,
1181
],
[
1181,
24,
1097
]
],
[
[
543,
24,
971
],
[
971,
63,
1097
]
],
[
[
543,
24,
77
],
[
77,
... | [
[
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lasmiditan"
]
],
[
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Terfenadine"
],
[
... | Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Terfenadine and Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Lasmiditan
Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gi... |
DB08875 | DB14568 | 1,618 | 982 | [
"DDInter262",
"DDInter1000"
] | Cabozantinib | Ivosidenib | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivoside... | Major | 2 | [
[
[
1618,
25,
982
]
],
[
[
1618,
62,
112
],
[
112,
23,
982
]
],
[
[
1618,
63,
1101
],
[
1101,
23,
982
]
],
[
[
1618,
63,
543
],
[
543,
... | [
[
[
"Cabozantinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
]
],
[
[
"Cabozantinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metro... | Cabozantinib may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and ... |
DB00655 | DB06777 | 559 | 780 | [
"DDInter682",
"DDInter348"
] | Estrone | Chenodeoxycholic acid | Estrone, one of the major mammalian estrogens, is an aromatized C18 steroid with a 3-hydroxyl group and a 17-ketone. It is produced in vivo from androstenedione or from testosterone via estradiol. It is produced primarily in the ovaries, placenta, and in peripheral tissues (especially adipose tissue) through conversion... | Chenodeoxycholic acid (or Chenodiol) is an epimer of ursodeoxycholic acid (DB01586). Chenodeoxycholic acid is a bile acid naturally found in the body. It works by dissolving the cholesterol that makes gallstones and inhibiting production of cholesterol in the liver and absorption in the intestines, which helps to decre... | Moderate | 1 | [
[
[
559,
24,
780
]
],
[
[
559,
6,
8374
],
[
8374,
45,
780
]
],
[
[
559,
21,
28890
],
[
28890,
60,
780
]
],
[
[
559,
1,
380
],
[
380,
... | [
[
[
"Estrone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chenodeoxycholic acid"
]
],
[
[
"Estrone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compou... | Estrone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Chenodeoxycholic acid (Compound)
Estrone (Compound) causes Myocardial infarction (Side Effect) and Myocardial infarction (Side Effect) is caused by Chenodeoxycholic acid (Compound)
Estrone (Compound) resembles Conjugated estrogens (Compound) and Conju... |
DB06176 | DB11853 | 1,342 | 230 | [
"DDInter1616",
"DDInter1577"
] | Romidepsin | Relugolix | Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. | Relugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist used in the treatment of several hormone-responsive conditions. It was first approved in Japan in 2019, under the brand name Relumina, for the symptomatic treatment of uterine fibroids, and more recently by the United States' FDA in 2020, under th... | Moderate | 1 | [
[
[
1342,
24,
230
]
],
[
[
1342,
24,
129
],
[
129,
23,
230
]
],
[
[
1342,
62,
112
],
[
112,
23,
230
]
],
[
[
1342,
24,
1476
],
[
1476,
... | [
[
[
"Romidepsin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Relugolix"
]
],
[
[
"Romidepsin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[
... | Romidepsin may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may cause a minor interaction that can limit clinical effects when taken with Relugolix
Romidepsin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metr... |
DB01576 | DB09082 | 93 | 659 | [
"DDInter526",
"DDInter1934"
] | Dextroamphetamine | Vilanterol | Dextroamphetamine is the dextrorotatory enantiomer of amphetamine. Dextroamphetamine was approved by the FDA in 2001 for the treatment of attention deficit hyperactivity disorder[L6010,Label]. | Vilanterol is a selective long-acting β2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma. This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor patient compliance (due to the frequency of dosing regimens or complexities of drug... | Moderate | 1 | [
[
[
93,
24,
659
]
],
[
[
93,
1,
1161
],
[
1161,
24,
659
]
],
[
[
93,
64,
222
],
[
222,
24,
659
]
],
[
[
93,
63,
1264
],
[
1264,
24,
... | [
[
[
"Dextroamphetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Dextroamphetamine",
"{u} (Compound) resembles {v} (Compound)",
"Selegiline"
],
[
"Selegiline",
"{u} may c... | Dextroamphetamine (Compound) resembles Selegiline (Compound) and Selegiline may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Dextroamphetamine may lead to a major life threatening interaction when taken with Sibutramine and Sibutramine may cause a moderate interaction that coul... |
DB00773 | DB08826 | 896 | 1,292 | [
"DDInter702",
"DDInter489"
] | Etoposide | Deferiprone | A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitoti... | Deferiprone is an oral iron chelator used as a second line agent in thalassemia syndromes when iron overload from blood transfusions occurs. Thalassemias are a type of hereditary anaemia due a defect in the production of hemoglobin. As a result, erythropoiesis, the production of new red blood cells, is impaired. FDA ap... | Major | 2 | [
[
[
896,
25,
1292
]
],
[
[
896,
21,
28809
],
[
28809,
60,
1292
]
],
[
[
896,
24,
1017
],
[
1017,
63,
1292
]
],
[
[
896,
24,
45
],
[
45,
... | [
[
[
"Etoposide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deferiprone"
]
],
[
[
"Etoposide",
"{u} (Compound) causes {v} (Side Effect)",
"Diarrhoea"
],
[
"Diarrhoea",
"{u} (Side Effect) is caused by {v} (Compo... | Etoposide (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Deferiprone (Compound)
Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Deferipr... |
DB00489 | DB05294 | 17 | 1,069 | [
"DDInter1704",
"DDInter1917"
] | Sotalol | Vandetanib | Sotalol is a methanesulfonanilide developed in 1960. It was the first of the class III anti arrhythmic drugs. Sotalol was first approved as an oral tablet on 30 October 1992. A racemic mixture of sotalol is currently formulated as a tablet, oral solution, and intravenous injection indicated for life threatening ventric... | Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types. On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients. | Major | 2 | [
[
[
17,
25,
1069
]
],
[
[
17,
21,
28719
],
[
28719,
60,
1069
]
],
[
[
17,
23,
112
],
[
112,
23,
1069
]
],
[
[
17,
25,
659
],
[
659,
... | [
[
[
"Sotalol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vandetanib"
]
],
[
[
"Sotalol",
"{u} (Compound) causes {v} (Side Effect)",
"Pain"
],
[
"Pain",
"{u} (Side Effect) is caused by {v} (Compound)",
"V... | Sotalol (Compound) causes Pain (Side Effect) and Pain (Side Effect) is caused by Vandetanib (Compound)
Sotalol may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Vandetanib
Sotalol ma... |
DB00270 | DB09065 | 1,428 | 760 | [
"DDInter993",
"DDInter424"
] | Isradipine | Cobicistat | Isradipine belongs to the dihydropyridine (DHP) class of calcium channel blockers (CCBs), the most widely used class of CCBs. It is structurally related to felodipine, nifedipine, and nimodipine and is the most potent calcium-channel blocking agent of the DHP class. Isradipine binds to calcium channels with high affini... | Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic e... | Moderate | 1 | [
[
[
1428,
24,
760
]
],
[
[
1428,
24,
1101
],
[
1101,
23,
760
]
],
[
[
1428,
24,
723
],
[
723,
24,
760
]
],
[
[
1428,
1,
84
],
[
84,
... | [
[
[
"Isradipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
]
],
[
[
"Isradipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
... | Isradipine may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Cobicistat
Isradipine may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepita... |
DB00586 | DB12615 | 1,512 | 1,381 | [
"DDInter537",
"DDInter1482"
] | Diclofenac | Plazomicin | Diclofenac is a phenylacetic acid derivative and non-steroidal anti-inflammatory drug (NSAID).[label] NSAIDs inhibit cyclooxygenase (COX)-1 and-2 which are the enzyme responsible for producing prostaglandins (PGs). PGs contribute to inflammation and pain signalling. Diclofenac, like other NSAIDs, is often used as first... | Developed by Achaogen biopharmaceuticals, plazomicin is a next-generation aminoglycoside synthetically derived from . The structure of plazomicin was established via appending hydroxylaminobutyric acid to at position 1 and 2-hydroxyethyl group at position 6' . It was designed to evade all clinically relevant aminoglyco... | Moderate | 1 | [
[
[
1512,
24,
1381
]
],
[
[
1512,
24,
1479
],
[
1479,
24,
1381
]
],
[
[
1512,
63,
91
],
[
91,
24,
1381
]
],
[
[
1512,
64,
663
],
[
663,
... | [
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Plazomicin"
]
],
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic acid"
]... | Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Plazomicin
Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with V... |
DB01591 | DB08816 | 667 | 578 | [
"DDInter1696",
"DDInter1802"
] | Solifenacin | Ticagrelor | Solifenacin is a competitive muscarinic receptor antagonist indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency. It has a long duration of action as it is usually taken once daily. Solifenacin was granted FDA approval on 19 November 2004. | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagre... | Moderate | 1 | [
[
[
667,
24,
578
]
],
[
[
667,
6,
8374
],
[
8374,
45,
578
]
],
[
[
667,
21,
28646
],
[
28646,
60,
578
]
],
[
[
667,
25,
1011
],
[
1011,
... | [
[
[
"Solifenacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
]
],
[
[
"Solifenacin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)... | Solifenacin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ticagrelor (Compound)
Solifenacin (Compound) causes Unspecified disorder of skin and subcutaneous tissue (Side Effect) and Unspecified disorder of skin and subcutaneous tissue (Side Effect) is caused by Ticagrelor (Compound)
Solifenacin may lead t... |
DB04855 | DB13074 | 540 | 877 | [
"DDInter602",
"DDInter1110"
] | Dronedarone | Macimorelin | Dronedarone is a Class III antiarrhythmic drug that works to restore the normal sinus rhythm in patients with paroxysmal or persistent atrial fibrillation. Atrial fibrillation is a common sustained arrhythmia where the treatment primarily focuses on stroke prevention and symptom management. It is managed by rate contro... | Macimorelin, a novel and orally active ghrelin mimetic that stimulates GH secretion, is used in the diagnosis of adult GH deficiency (AGHD). More specifically, macimorelin is a peptidomimetic growth hormone secretagogue (GHS) that acts as an agonist of GH secretagogue receptor, or ghrelin receptor (GHS-R1a) to dose-dep... | Major | 2 | [
[
[
540,
25,
877
]
],
[
[
540,
62,
112
],
[
112,
23,
877
]
],
[
[
540,
24,
1320
],
[
1320,
24,
877
]
],
[
[
540,
25,
913
],
[
913,
2... | [
[
[
"Dronedarone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
]
],
[
[
"Dronedarone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metron... | Dronedarone may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Macimorelin
Dronedarone may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Ela... |
DB08893 | DB11730 | 271 | 351 | [
"DDInter1229",
"DDInter1588"
] | Mirabegron | Ribociclib | Mirabegron is a sympathomimetic beta-3 adrenergic receptor agonist used to relax the smooth muscle of the bladder in the treatment of urinary frequency and incontinence. It is unique amongst overactive bladder treatment options in that, unlike other treatments such as [solifenacin] and [darifenacin], it lacks significa... | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced p... | Minor | 0 | [
[
[
271,
23,
351
]
],
[
[
271,
23,
283
],
[
283,
62,
351
]
],
[
[
271,
62,
597
],
[
597,
24,
351
]
],
[
[
271,
23,
951
],
[
951,
24,... | [
[
[
"Mirabegron",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ribociclib"
]
],
[
[
"Mirabegron",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fedratinib"
],
[
... | Mirabegron may cause a minor interaction that can limit clinical effects when taken with Fedratinib and Fedratinib may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Mirabegron may cause a minor interaction that can limit clinical effects when taken with Chloramphenicol and Chloram... |
DB00427 | DB01563 | 1,233 | 680 | [
"DDInter1879",
"DDInter349"
] | Triprolidine | Chloral hydrate | First generation histamine H1 antagonist used in allergic rhinitis; asthma; and urticaria. It is a component of cough and cold medicines. It may cause drowsiness. | A hypnotic and sedative used in the treatment of insomnia. The safety margin is too narrow for chloral hydrate to be used as a general anesthetic in humans, but it is commonly used for that purpose in animal experiments. It is no longer considered useful as an anti-anxiety medication. | Moderate | 1 | [
[
[
1233,
24,
680
]
],
[
[
1233,
24,
272
],
[
272,
24,
680
]
],
[
[
1233,
24,
1609
],
[
1609,
63,
680
]
],
[
[
1233,
63,
1242
],
[
1242,
... | [
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloral hydrate"
]
],
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
... | Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Chloral hydrate
Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with ... |
DB00321 | DB05812 | 21 | 1,374 | [
"DDInter78",
"DDInter8"
] | Amitriptyline | Abiraterone | Amitriptyline is a tricyclic antidepressant that has been used to treat depression for decades. ELAVIL, a previously approved branded product of amitriptyline, was first approved by the FDA in 1961. Amitriptyline has been investigated in the treatment of pain-related conditions, attributed to its analgesic properties. | Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 201... | Moderate | 1 | [
[
[
21,
24,
1374
]
],
[
[
21,
6,
1829
],
[
1829,
45,
1374
]
],
[
[
21,
21,
28661
],
[
28661,
60,
1374
]
],
[
[
21,
23,
112
],
[
112,
... | [
[
[
"Amitriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
]
],
[
[
"Amitriptyline",
"{u} (Compound) binds {v} (Gene)",
"ALB"
],
[
"ALB",
"{u} (Gene) is bound by {v} (Compound)"... | Amitriptyline (Compound) binds ALB (Gene) and ALB (Gene) is bound by Abiraterone (Compound)
Amitriptyline (Compound) causes Acute coronary syndrome (Side Effect) and Acute coronary syndrome (Side Effect) is caused by Abiraterone (Compound)
Amitriptyline may cause a minor interaction that can limit clinical effects when... |
DB01175 | DB09472 | 318 | 1,383 | [
"DDInter672",
"DDInter1693"
] | Escitalopram | Sodium sulfate | Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic [citalopram]. It is used to restore serotonergic function in the treatment of depression and anxiety.[L8513,L8516,L8522] Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible ... | Sodium Sulfate Anhydrous is the anhydrous, sodium salt form of sulfuric acid. Sodium sulfate anhydrous disassociates in water to provide sodium ions and sulfate ions. Sodium ion is the principal cation of the extracellular fluid and plays a large part in the therapy of fluid and electrolyte disturbances. Sodium sulfate... | Moderate | 1 | [
[
[
318,
24,
1383
]
],
[
[
318,
25,
609
],
[
609,
24,
1383
]
],
[
[
318,
24,
1311
],
[
1311,
24,
1383
]
],
[
[
318,
64,
521
],
[
521,
... | [
[
[
"Escitalopram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Escitalopram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clarithromycin"
],
[
... | Escitalopram may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Escitalopram may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide and M... |
DB01324 | DB13142 | 178 | 841 | [
"DDInter1490",
"DDInter274"
] | Polythiazide | Calcium glubionate anhydrous | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p826) | Calcium glubionate (or glubionate calcium) is a mineral supplement to prevent or treat low blood calcium levels in people who do not get enough calcium from their diets. | Moderate | 1 | [
[
[
178,
24,
841
]
],
[
[
178,
62,
1669
],
[
1669,
24,
841
]
],
[
[
178,
1,
504
],
[
504,
24,
841
]
],
[
[
178,
62,
1669
],
[
1669,
... | [
[
[
"Polythiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium glubionate anhydrous"
]
],
[
[
"Polythiazide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Minocyc... | Polythiazide may cause a minor interaction that can limit clinical effects when taken with Minocycline and Minocycline may cause a moderate interaction that could exacerbate diseases when taken with Calcium glubionate anhydrous
Polythiazide (Compound) resembles Hydrochlorothiazide (Compound) and Hydrochlorothiazide may... |
DB09074 | DB11793 | 1,362 | 738 | [
"DDInter1327",
"DDInter1297"
] | Olaparib | Niraparib | Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Ol... | Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, f... | Moderate | 1 | [
[
[
1362,
24,
738
]
],
[
[
1362,
63,
1213
],
[
1213,
24,
738
]
],
[
[
1362,
24,
1033
],
[
1033,
63,
738
]
],
[
[
1362,
24,
496
],
[
496,
... | [
[
[
"Olaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
]
],
[
[
"Olaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
],
[
"D... | Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib and Alpelisib may ... |
DB00388 | DB00747 | 1,636 | 1,442 | [
"DDInter1453",
"DDInter1647"
] | Phenylephrine | Scopolamine | Phenylephrine is an alpha-1 adrenergic receptor agonist used to treat hypotension,[L9416,L9410] dilate the pupil, and induce local vasoconstriction. The action of phenylephrine, or neo-synephrine, was first described in literature in the 1930s. Phenylephrine was granted FDA approval in 1939. | Scopolamine is a tropane alkaloid isolated from members of the _Solanaceae_ family of plants, similar to [atropine] and [hyoscyamine], all of which structurally mimic the natural neurotransmitter [acetylcholine].[A228423, A228763] Scopolamine was first synthesized in 1959, but to date, synthesis remains less efficient ... | Moderate | 1 | [
[
[
1636,
24,
1442
]
],
[
[
1636,
24,
19
],
[
19,
24,
1442
]
],
[
[
1636,
21,
29326
],
[
29326,
60,
1442
]
],
[
[
1636,
25,
551
],
[
551,
... | [
[
[
"Phenylephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Scopolamine"
]
],
[
[
"Phenylephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hyoscyamine"
],
... | Phenylephrine may cause a moderate interaction that could exacerbate diseases when taken with Hyoscyamine and Hyoscyamine may cause a moderate interaction that could exacerbate diseases when taken with Scopolamine
Phenylephrine (Compound) causes Photophobia (Side Effect) and Photophobia (Side Effect) is caused by Scopo... |
DB00836 | DB04948 | 543 | 1,084 | [
"DDInter1088",
"DDInter1083"
] | Loperamide | Lofexidine | Loperamide is an anti-diarrheal agent that is available as various over-the-counter products for treating diarrhea. The drug was first synthesized in 1969 and used medically in 1976. It is a highly lipophilic synthetic phenylpiperidine opioid that is structurally similar to opiate receptor agonists such as [diphenoxyla... | Lofexidine is a non-opioid centrally acting alpha2-adrenergic receptor agonist that was first approved for the treatment of opioid withdrawal in the United Kingdom in 1992. It was first studied for use as an antihypertensive in 1980, but its researched was stopped as it was found less effective for the treatment of hyp... | Moderate | 1 | [
[
[
543,
24,
1084
]
],
[
[
543,
24,
1617
],
[
1617,
1,
1084
]
],
[
[
543,
24,
112
],
[
112,
23,
1084
]
],
[
[
543,
63,
618
],
[
618,
... | [
[
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lofexidine"
]
],
[
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apraclonidine"
],
[... | Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Apraclonidine and Apraclonidine (Compound) resembles Lofexidine (Compound)
Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction t... |
DB00679 | DB00719 | 684 | 1,219 | [
"DDInter1796",
"DDInter149"
] | Thioridazine | Azatadine | A phenothiazine antipsychotic used in the management of psychoses, including schizophrenia, and in the control of severely disturbed or agitated behavior. It has little antiemetic activity. Thioridazine has a higher incidence of antimuscarinic effects, but a lower incidence of extrapyramidal symptoms, than chlorpromazi... | Antihistamines such as azatadine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine which are mediated through activation of H1- receptor sites and thereby reduce the intensity of allergic reactions and tissue inj... | Moderate | 1 | [
[
[
684,
24,
1219
]
],
[
[
684,
63,
13
],
[
13,
24,
1219
]
],
[
[
684,
24,
830
],
[
830,
1,
1219
]
],
[
[
684,
6,
10104
],
[
10104,
... | [
[
[
"Thioridazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azatadine"
]
],
[
[
"Thioridazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyproheptadine"
],
... | Thioridazine may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Azatadine
Thioridazine may cause a moderate interaction that could exacerbate diseases when taken with Phenindami... |
DB00450 | DB04868 | 78 | 478 | [
"DDInter603",
"DDInter1293"
] | Droperidol | Nilotinib | A butyrophenone with general properties similar to those of haloperidol. It is used in conjunction with an opioid analgesic such as fentanyl to maintain the patient in a calm state of neuroleptanalgesia with indifference to surroundings but still able to cooperate with the surgeon. It is also used as a premedicant, as ... | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Major | 2 | [
[
[
78,
25,
478
]
],
[
[
78,
21,
28963
],
[
28963,
60,
478
]
],
[
[
78,
23,
112
],
[
112,
23,
478
]
],
[
[
78,
24,
1559
],
[
1559,
2... | [
[
[
"Droperidol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nilotinib"
]
],
[
[
"Droperidol",
"{u} (Compound) causes {v} (Side Effect)",
"Anxiety"
],
[
"Anxiety",
"{u} (Side Effect) is caused by {v} (Compound)... | Droperidol (Compound) causes Anxiety (Side Effect) and Anxiety (Side Effect) is caused by Nilotinib (Compound)
Droperidol may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Nilotinib
... |
DB01208 | DB11113 | 945 | 657 | [
"DDInter1705",
"DDInter307"
] | Sparfloxacin | Castor oil | Sparfloxacin is a fluoroquinolone antibiotic indicated for bacterial infections. Sparfloxacin exerts its antibacterial activity by inhibiting DNA gyrase, a bacterial topoisomerase. DNA gyrase is an essential enzyme which controls DNA topology and assists in DNA replication, repair, deactivation, and transcription. | Castor oil is a vegetable oil obtained by pressing the seeds of the castor oil plant (_Ricinus communis_ L.) mainly cultivated in India, South America, Africa, and China. Castor oil is a rich source of , which represents up to 90% of the total castor oil content. It also consists up to 4% linoleic, 3% oleic, 1% stearic... | Moderate | 1 | [
[
[
945,
24,
657
]
],
[
[
945,
25,
927
],
[
927,
63,
657
]
],
[
[
945,
25,
1491
],
[
1491,
24,
657
]
],
[
[
945,
64,
891
],
[
891,
2... | [
[
[
"Sparfloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
]
],
[
[
"Sparfloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
],
[
"Encor... | Sparfloxacin may lead to a major life threatening interaction when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Sparfloxacin may lead to a major life threatening interaction when taken with Midostaurin and Midostaurin may cause a moder... |
DB01166 | DB15233 | 477 | 1,650 | [
"DDInter379",
"DDInter142"
] | Cilostazol | Avapritinib | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both prim... | Avapritinib, or BLU-285, is a selective tyrosine kinase inhibitor of KIT and platelet derived growth factor receptor alpha indicated for the treatment of unresectable, metastatic gastrointestinal stromal tumors and advanced systemic mastocytosis.[A189339,L40363] It is one of the first medications available for the trea... | Major | 2 | [
[
[
477,
25,
1650
]
],
[
[
477,
24,
1478
],
[
1478,
24,
1650
]
],
[
[
477,
63,
522
],
[
522,
24,
1650
]
],
[
[
477,
25,
982
],
[
982,
... | [
[
[
"Cilostazol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Avapritinib"
]
],
[
[
"Cilostazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
],
[
"Ivacaftor"... | Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Avapritinib
Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Zafirlukast and Zafirl... |
DB06228 | DB06717 | 792 | 875 | [
"DDInter1609",
"DDInter778"
] | Rivaroxaban | Fosaprepitant | Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be t... | Fosaprepitant is an intravenously administered antiemetic drug. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment. | Moderate | 1 | [
[
[
792,
24,
875
]
],
[
[
792,
63,
723
],
[
723,
1,
875
]
],
[
[
792,
21,
29340
],
[
29340,
60,
875
]
],
[
[
792,
63,
222
],
[
222,
... | [
[
[
"Rivaroxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosaprepitant"
]
],
[
[
"Rivaroxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
... | Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant (Compound) resembles Fosaprepitant (Compound)
Rivaroxaban (Compound) causes Stevens-Johnson syndrome (Side Effect) and Stevens-Johnson syndrome (Side Effect) is caused by Fosaprepitant (Compound)
Rivaro... |
DB09118 | DB09272 | 1,580 | 412 | [
"DDInter1711",
"DDInter632"
] | Stiripentol | Eluxadoline | Stiripentol is an antiepileptic agent that is an aromatic allylic alcohol drug, which makes it structurally unique from other antiepileptic drugs.[A19740, A250825] The clinical development and marketing of stiripentol were first delayed due to the drug's potent inhibitory effects on hepatic cytochrome P450 (CYP) enzyme... | Eluxadoline is a mixed mu-opioid receptor agonist, kappa-opioid receptor agonist, and a-delta opioid receptor antagonist indicated for use in diarrhea-predominant irritable bowel syndrome (IBS-D). The mu-, kappa-, and delta-opioid receptors mediate endogenous and exogenous opioid response in the central nervous system ... | Moderate | 1 | [
[
[
1580,
24,
412
]
],
[
[
1580,
63,
1594
],
[
1594,
24,
412
]
],
[
[
1580,
24,
407
],
[
407,
63,
412
]
],
[
[
1580,
64,
1425
],
[
1425,
... | [
[
[
"Stiripentol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eluxadoline"
]
],
[
[
"Stiripentol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[... | Stiripentol may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline
Stiripentol may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium ma... |
DB00501 | DB00916 | 752 | 112 | [
"DDInter380",
"DDInter1202"
] | Cimetidine | Metronidazole | A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant ... | Metronidazole is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics. It is frequently used to treat gastrointestinal infections as well as trichomoniasis and giardiasis, and amebiasis which are parasitic infections.[A181036,A181039] Metronidazole has been used as an antibiotic for several ... | Minor | 0 | [
[
[
752,
23,
112
]
],
[
[
752,
23,
458
],
[
458,
40,
112
]
],
[
[
752,
6,
3486
],
[
3486,
45,
112
]
],
[
[
752,
21,
29310
],
[
29310,
... | [
[
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
]
],
[
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tinidazole"
],
[
... | Cimetidine may cause a minor interaction that can limit clinical effects when taken with Tinidazole and Tinidazole (Compound) resembles Metronidazole (Compound)
Cimetidine (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Metronidazole (Compound)
Cimetidine (Compound) causes Toxic epidermal necrolysis (Side ... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.